Coates International 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 26, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	COATES INTERNATIONAL LTD \DE\
Entity Central Index Key	948426
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Public Float			$8,742,707
Entity Common Stock, Shares Outstanding		577,932,422

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash	$263,526	$49,274
Inventory, net	47,274	111,752
Deferred offering costs and other assets	44,874	12,423
Total Current Assets	355,674	173,449
Property, plant and equipment, net	2,119,010	2,179,646
Deferred licensing costs, net	46,732	51,016
Total Assets	2,521,416	2,404,111
Current Liabilities
Accounts payable and accrued liabilities	1,982,777	2,263,947
Promissory notes to related parties	1,565,505	603,138
Mortgage loan payable	1,448,284	1,513,284
Deferred compensation payable	1,079,904	287,664
Current portion of license deposits	517,500	19,200
Convertible promissory notes, net of unamortized discount	500,905	125,018
Derivative liability related to convertible promissory notes	475,695	366,590
Current portion of finance lease obligation, net of unamortized discount	62,102	43,311
Unearned revenue	19,124	19,124
10% convertible note		10,000
Total Current Liabilities	7,651,796	5,251,276
Non-current portion of license deposits	283,800	303,000
Non-current portion of finance lease obligation, net of unamortized discount	19,349	81,452
Total Liabilities	7,954,945	5,635,728
Commitments and Contingencies
Stockholders' Deficiency
Preferred stock, $0.001 par value, 100,000,000 shares authorized:
Series A preferred stock, 1,000,000 designated, 50,000 and 141,473 shares issued and outstanding at December 31, 2014 and 2013, respectively	50	141
Series B convertible preferred stock, 1,000,000 shares designated, 585,502 and no shares issued and outstanding at December 31, 2014 and 2013, respectively	586
Common stock, $0.0001 par value, 1,000,000,000 shares authorized, 443,508,090 and 327,749,176 shares issued and outstanding at December 31, 2014 and 2013, respectively	44,351	32,775
Additional paid-in capital	41,288,663	30,712,778
Accumulated deficit	-46,767,179	-33,977,311
Total Stockholders' Deficiency	-5,433,529	-3,231,617
Total Liabilities and Stockholders' Deficiency	$2,521,416	$2,404,111

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	100,000,000	100,000,000
Common stock, par value	$0.00	$0.00
Common stock, authorized shares	1,000,000,000	1,000,000,000
Common stock, issued shares	443,508,090	327,749,176
Common stock, outstanding shares	443,508,090	327,749,176
Series A Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	100,000,000	100,000,000
Series A preferred stock, designated shares	1,000,000	1,000,000
Series A Preferred stock, issued shares	50,000	141,473
Series A Preferred stock, outstanding shares	50,000	141,473
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	100,000,000	100,000,000
Series B convertible preferred stock, designated shares	1,000,000	1,000,000
Series B Preferred stock, issued shares	585,502
Series B Preferred stock, outstanding shares	585,502

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statements of Operations [Abstract]
Sublicensing fee revenue	$19,200	$19,200
Total Revenues	19,200	19,200
Expenses:
Marketing expenses	48,095	3,205
Research and development costs	487,767	261,161
Compensation and benefits	10,400,971	1,047,283
General and administrative expenses	575,235	610,324
Depreciation and amortization	64,920	66,485
Total Expenses	11,576,988	1,988,458
Loss from Operations	-11,557,788	-1,969,258
Other Expense:
Increase in estimated fair value of embedded derivative liabilities	-109,105	-210,390
Loss on conversion of convertible notes	-94,632
Interest expense, net	-1,028,343	-570,542
Total other expense	-1,232,080	-780,932
Loss Before Income Taxes	-12,789,868	-2,750,190
Provision for income taxes
Net Loss	($12,789,868)	($2,750,190)
Basic net loss per share	($0.03)	($0.01)
Basic weighted average shares outstanding	385,372,919	334,010,734
Diluted net loss per share	($0.03)	($0.01)
Diluted weighted average shares outstanding	385,372,919	334,010,734

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity Deficiency (USD $)	Total	Series A Preferred Stock, $0.001 par value per share	Series B Preferred Stock, $0.001 par value per share	Common Stock, $0.0001 par value per share	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	($3,937,287)	$73		$30,508	$27,259,253	($31,227,121)
Beginning Balance, shares at Dec. 31, 2012		72,883		305,078,818
Issuance of anti-dilution shares of Series A Preferred stock to George J. Coates	170,362	68			170,294
Issuance of anti-dilution shares of Series A Preferred stock to George J. Coates, shares		68,590
Issuance of anti-dilution shares of Common Stock to George J. Coates	2,181,483			3,504	2,177,979
Issuance of anti-dilution shares of Common Stock to George J. Coates, shares				35,037,131
Cancelation of anti-dilution shares of Common Stock to George J. Coates				-3,504	3,504
Cancelation of anti-dilution shares of Common Stock to George J. Coates, shares				-35,037,131
Issuance of common stock and warrants to son of a director	125,000			467	124,533
Issuance of common stock and warrants to son of a director, shares				4,666,666
Conversion of convertible promissory notes	271,056			1,372	269,684
Conversion of convertible promissory notes, shares				13,718,349
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP	155,505			361	155,144
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP, shares				3,618,676
Exercise of stock purchase warrants	10,000			67	9,933
Exercise of stock purchase warrants, shares				666,667
Beneficial conversion feature on convertible promissory notes	293,536				293,536
Stock compensation expense	248,918				248,918
Net loss for the year	-2,750,190					-2,750,190
Ending Balance at Dec. 31, 2013	-3,231,617	141		32,775	30,712,778	-33,977,311
Ending Balance, shares at Dec. 31, 2013		141,473		327,749,176
Issuance of anti-dilution shares of Series A Preferred stock to George J. Coates	169,452	90			169,362
Issuance of anti-dilution shares of Series A Preferred stock to George J. Coates, shares		90,191
Conversion of Series A Preferred Stock held by George J. Coaters into Series B Convertible Preferred Stock	4,051,069	-181	257		4,050,993
Conversion of Series A Preferred Stock held by George J. Coaters into Series B Convertible Preferred Stock, shares		-181,664	256,664
Issuance of anti-dilution shares of Series B Convertible Preferred Stock to related parties	4,511,671		329		4,511,342
Issuance of anti-dilution shares of Series B Convertible Preferred Stock to related parties, shares			328,838
Stock-based compensation award to George J. Coates for lost benefits of property ownership	950,000			3,770	946,230
Stock-based compensation award to George J. Coates for lost benefits of property ownership, shares				37,698,413
Issuance of common stock and warrants to son of a director	515,000			1,646	513,354
Issuance of common stock and warrants to son of a director, shares				16,456,076
Conversion of convertible promissory notes	626,785			4,825	621,960
Conversion of convertible promissory notes, shares				48,251,621
Conversion of promissory notes to related parties into common stock	237,187			845	236,342
Conversion of promissory notes to related parties into common stock, shares				8,449,401
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP	161,636			440	161,196
Issuance of common stock under equity line of credit with Dutchess Opportunity Fund II, LP, shares				4,403,403
Exercise of stock purchase warrants	10,000			50	9,950
Exercise of stock purchase warrants, shares				500,000
Conversion of additional paid-in capital into note due to related party	-1,462,093				-1,462,093
Beneficial conversion feature on convertible promissory notes	800,182				800,182
Stock compensation expense	17,067				17,067
Net loss for the year	-12,789,868					-12,789,868
Ending Balance at Dec. 31, 2014	($5,433,529)	$50	$586	$44,351	$41,288,663	($46,767,179)
Ending Balance, shares at Dec. 31, 2014		50,000	585,502	443,508,090

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net Cash Flows Used in Operating Activities
Net loss for the year	($12,789,868)	($2,750,190)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	10,174,258	634,938
Interest and amortization of discount on convertible promissory notes and finance lease obligation	736,622	301,117
Increase in fair value of embedded derivative liabilities	109,105	210,391
Loss on conversion of convertible notes	94,632
Depreciation and amortization	64,920	66,485
Amortization of deferred financing costs	10,246	10,246
Negotiated settlement of accounts payable	-20,266
Recognition of non-cash licensing revenues	-19,200	-19,200
Changes in Operating Assets and Liabilities:
Inventory, net	64,478	636
Deferred offering costs and other assets	-32,451	-3,783
Accounts payable and accrued liabilities	-281,170	466,510
Deferred compensation payable	317,240	287,664
Net Cash Used in Operating Activities	-1,571,454	-795,186
Net Cash Provided by (Used in) Investing Activities
Cash Flows Provided by Financing Activities:
Issuances of convertible promissory notes	995,583	398,000
Issuance of common stock and warrants to the son of a director	515,000	125,000
Deposit on tentative China sublicense agreement	498,300
Issuance of common stock under equity line of credit	161,636	155,506
Proceeds from exercise of stock warrants	10,000	10,000
Issuance of promissory notes to related parties		172,093
Repayment of promissory notes to related parties	-280,000	-76,650
Repayment of mortgage loan	-65,000	-61,716
Finance lease obligation payments	-49,813	-23,626
Proceeds from sale/leaseback of equipment		132,550
Net Cash Provided by Financing Activities	1,785,706	831,157
Net Increase in Cash	214,252	35,971
Cash, beginning of period	49,274	13,303
Cash, end of period	263,526	49,274
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest	165,555	138,977
Supplemental Disclosure of Non-cash Financing Activities:
Conversion of additional paid in capital into promissory note to Gregory Coates	1,462,093
Conversion of convertible promissory notes	626,785	271,056
Conversion of Promissory Notes to Related Parties into Common Stock	219,726
Issuance of common stock for anti-dilution, net of cancelled anti-dilution common shares		2,181,483
Total	$2,308,604	$2,452,539

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
The Company and Summary of Significant Accounting Policies [Abstract]
THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Organization
	Coates International, Ltd. is a Delaware corporation organized in October 1991 as successor-in-interest to a Delaware corporation of the same name incorporated in August 1988.  Coates International, Ltd. operates in Wall Township, New Jersey.
	The Company has acquired the exclusive licensing rights for the Coates spherical rotary valve (“CSRV®”) system technology in North America, Central America and South America (the “CSRV® License”). The CSRV® system technology has been developed over a period of more than 20 years by the Company’s founder George J. Coates and his son Gregory G. Coates. The CSRV® system technology is adaptable for use in piston-driven internal combustion engines of many types and has been patented in the United States and numerous countries throughout the world.
	The CSRV® system technology is designed to replace the intake and exhaust conventional “poppet valves” currently used in almost all piston-driven, automotive, truck, motorcycle, marine and electric power generator engines, among others. Unlike conventional valves which protrude into the engine cylinder, the CSRV® system technology utilizes spherical valves that rotate in a cavity formed between a two-piece cylinder head. The CSRV® system technology utilizes significantly fewer moving parts than conventional poppet valve assemblies. As a result of these design improvements, management believes that engines incorporating the CSRV® system technology (“Coates Engines”) will last significantly longer and will require less lubrication over the life of the engine, as compared to conventional engines. In addition, CSRV® Engines can be designed with larger openings into the engine cylinder than with conventional valves so that more fuel and air can be inducted into, and expelled from, the cylinder in a shorter period of time. Larger valve openings permit higher revolutions-per-minute (RPM’s) and permit higher compression ratios with lower combustion chamber temperatures, allowing the Coates Engine to produce more power than equivalent conventional engines. The extent, to which higher RPM’s, greater volumetric efficiency and thermal efficiency can be achieved with the CSRV® system technology, is a function of the engine design and application.
	Hydrogen Reactor Technology Owned by George J. Coates
	George J. Coates has developed a hydrogen reactor, which rearranges H2O water molecules into HOH molecules also known as Hydroxy-Gas. The Hydroxy-Gas produced by the hydrogen reactor is then harvested for use as a type of fuel. Mr. Coates intends to continue with development of this technology to enable the harvested Hydroxy-Gas to be utilized as the fuel source to power our patented CSRV® engines. The next phase of this research and development will focus on powering larger, industrial engines. If successful, this application will only require a ready supply of water and would be suitable for stationary engines and generators. Conventional internal combustion engines employing poppet valve assemblies require lubrication and would experience excessive heat and friction if powered with Hydroxy-Gas. This, in turn, would cause the engines to burn out in a rather short period of time. The materials and components of the CSRV® engines do not require such lubrication and because of their design, are able to operate relatively trouble-free on Hydroxy-Gas as the engine fuel. There can be no assurance that this technology can be developed successfully, or that if developed, it will be feasible to penetrate the internal combustion engine market with this technology. Applications for patent protection of this technology will be filed upon completion of the research and development. Although at this time no arrangements have been made between the Company and George J. Coates, owner of the technology, regarding licensing of the hydrogen reactor, Mr. Coates has provided his commitment to license this technology to the Company once the related patent protection is in place. Accordingly, the Company does not currently have any rights to manufacture, use, sell and distribute the Hydrogen Reactor technology, should it become commercially feasible to manufacture and distribute products powered by the Hydroxy-Gas fuel. The Company has been and continues to be responsible for all costs incurred related to the development of this technology.
	Basis of Presentation
	The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and rules and regulations of the Securities and Exchange Commission (the “SEC”).
	Since the Company’s inception, the Company has been responsible for the development costs of the CSRV® technology in order to optimize the value of the licensing rights and has incurred related operational costs, the bulk of which have been funded primarily through cash generated from licensing fees, sales of stock, short term convertible promissory notes, capital contributions, loans made by George J. Coates, Bernadette Coates, his spouse and certain directors, fees received from research and development of prototype models and a small number of CSRV® engine generator sales. The Company has incurred substantial cumulative losses from operations since its inception. Losses from operations are expected to continue until the Coates Engines are successfully introduced into and accepted in the marketplace, or the Company receives substantial licensing revenues. These losses from operations were substantially related to research and development of the Company’s intellectual property rights, patent filing and maintenance costs and general and administrative expenses. The Company has also incurred substantial non-cash expenses for stock-based compensation.
	As shown in the accompanying financial statements, the Company has incurred recurring losses from operations and, as of December 31, 2014, had a stockholders’ deficiency of ($5,434,000). The Company will be required to renegotiate the terms of an extension of a $1,448,000 mortgage loan which matures in July 2015 or successfully refinance the property with another mortgage lender, if possible. Failure to do so could adversely affect the Company’s financial position and results of operations. In addition, the current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest their funds and low investor confidence, has introduced additional risk and difficulty to the Company’s challenge to secure needed additional working capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management has instituted a cost control program intended to restrict variable costs to only those expenses that are necessary to complete its activities related to entering the production phase of operations, develop additional commercially feasible applications of the CSRV® system technology, seek additional sources of working capital and cover general and administrative costs in support of such activities. The Company has been actively undertaking efforts to secure new sources of working capital. At the December 31, 2014, the Company had negative working capital of ($7,296,000) compared with negative working capital of ($5,078,000) at the end of 2013.
	During the years ended December 31, 2014 and 2013, the Company raised $2,181,000 and $917,000, respectively, of new working capital from the following:
		Description		2014		2013
		Issuance of convertible promissory notes		$	996,000	$	398,000
		Sales of shares of common stock and warrants to the son of a director			515,000		125,000
		Deposit on non-exclusive distribution license with China-based company			498,000		-
		Sales of common stock under equity line of credit			162,000		156,000
		Proceeds from exercise of common stock warrants			10,000		10,000
		Proceeds from sale/leaseback of equipment			-		133,000
		Issuances of promissory notes to related parties, net of repayments			-		95,000
				$	2,181,000	$	917,000
	In the fourth quarter of 2011, the Company identified cracks on the lower engine heads of its Gen Sets that resulted from a defect in the manufacturing by one of its suppliers. Based on testing of the Gen Set to confirm the Company’s resolution of this problem, management believes it has determined the cause of this cracked head condition. The Company has placed orders for new production parts, including sets of engine heads and has also modified certain patterns with the goal of manufacturing a limited number of Gen Sets. Thereafter, it will undertake field testing of the Gen Sets, after which, it will begin to ramp-up production.
	The Company continues to actively seek out new sources of working capital; however, there can be no assurance that it will be successful in these efforts. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Certain amounts included in the accompanying financials statements for the year ended December 31, 2013 have been reclassified in order to make them comparable to the amounts presented for the year ended December 31, 2014.
	Majority-Owned Subsidiary
	CIL is currently the majority shareholder of Coates Hi-Tech Engines, Ltd., a Delaware corporation which was formed in July 2012. It has not commenced operations and has no assets.
	Revenue Recognition
	Sales and cost of sales are recognized at the time of shipment, provided the risk of loss has transferred to the customer and collection of the sales price is reasonably assured. Shipping arrangements and costs are the responsibility of the customer.
	Revenue from research and development activities is recognized when collection of the related revenues is reasonably assured and, when applicable, in accordance with Accounting Standards Update No. 2010-17, “Milestone Method of Revenue Recognition, a consensus of the FASB Emerging Issues Task Force”. This standard provides guidance on defining a milestone and permits recognition of revenue from research and development that is contingent upon achievement of one or more specified milestones defined in the research and development arrangements which meet specified criteria for such revenue recognition.
	Unearned revenue represents a deposit from a customer for a CSRV® Gen Set order. Revenue is recognized as described above.
	License deposits, which are non-refundable, were received from the granting of sublicenses and are recognized as earned, generally commencing upon the completion of certain tests of the CSRV® products and acceptance by the licensee. At that time, license revenue will be recognized ratably over the period of time that the sublicense has been granted using the straight-line method. Upon termination of a sublicense agreement, non-refundable license deposits, less any costs related to the termination of the sublicense agreement, are recognized as revenue. Revenue from research and development activities is recognized when earned and realization is reasonably assured, provided that financial risk has been transferred from the Company to its customer.
	The Company is recognizing the license deposit of $300,000 on the Canadian License as revenue on a straight-line basis over the approximate remaining life through 2027 of the last CSRV® technology patent in force.
	Research and Development
	Research and development costs are expensed when incurred. Included in accounts payable and accrued liabilities at December 31, 2014 and 2013 is $115,000 for the estimated remediation costs of previously sold Gen Sets that were determined to have cracked heads.
	Intellectual Property
	Under a licensing agreement with George J. Coates and Gregory G. Coates, the Company obtained the rights to manufacture, use and sell the CSRV® engine technology throughout the territory defined as the Western Hemisphere. In accordance with GAAP, the Company is not permitted to record a value for this intellectual property because it was obtained from principal stockholders, and, accordingly this intangible asset is not reflected in the accompanying financial statements.
	Licensing Costs
	Under the CSRV® Licensing Agreement for the CSRV® engine technology, the Company is responsible for all costs in connection with applying for and maintaining patents to protect the CSRV® system technology. Such costs are expensed as incurred.
	Advertising and Marketing Costs
	Advertising costs, which are included in marketing expenses, are expensed when incurred. Advertising expense amounted to $48,000 and $3,000 for the years ended December 31, 2014 and 2013, respectively. In the year ended December 31, 2014, advertising and marketing costs included $45,000 in fees to agents in China and the Middle East for their assistance in introducing our CSRV technology and presenting proposals to potential investors interested in entering into a sublicense arrangement with the Company.
	Stock-Based Compensation
	Stock-based compensation expense, which does not require any outlay of cash, consists of the following:
		●	The estimated fair value of shares of the Company’s capital stock issued to key employees for anti-dilution protection pursuant to a resolution of the board of directors. This includes restricted shares of Series A Preferred Stock and Series B Convertible Stock. In 2014, the Company arranged for an independent professional services firm to determine the estimated fair value of Series A Preferred Stock issued in August 2014 and Series B Preferred Stock issued in July 2014. The approach to arriving at the estimated fair value of the Series B Convertible Preferred Stock was determined to have a close correlation to the trading price of the Company’s common stock. Accordingly, upon each subsequent issuance of shares of Series B Convertible Preferred Stock, the original estimated fair value determined by the independent valuation is adjusted, on a pro rata basis, to reflect the closing price of the Company’s common stock on each date of issuance.
		●	Compensation expense relating to stock options and stock awards under its stock option and incentive plans is recognized as an expense using the fair value measurement method. Under the fair value method, the estimated fair value of awards to employees is charged to income on a straight-line basis over the requisite service period, which is the earlier of the employee’s retirement eligibility date or the vesting period of the award.
	Deferred Compensation
	Deferred compensation represents salaries of George J. Coates and Bernadette Coates earned but not paid in order to preserve the Company’s working capital. The Company intends to repay these amounts at such time that it has sufficient working capital and after the related party notes to George J. Coates and Bernadette Coates have been repaid with interest thereon. Also included in deferred compensation is the estimated amount of personal income taxes of George J. Coates that the Company is obligated to pay in connection with certain shares of stock that he received to compensate him for lost benefits of ownership of the Company’s headquarters, research and development and warehouse facility subsequent to the date he contributed this property to the Company, without having received any compensation therefor.
	Inventory
	Inventory consists of raw materials and work-in-process, including overhead and is stated at the lower of cost or market determined by the first-in, first-out method. Inventory items designated as obsolete or slow moving are reduced to net realizable value. Market value is determined using current replacement cost.
	Property, Plant and Equipment
	Property, plant and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful life of the assets: 40 years for buildings and building improvements, 3 to 7 years for machinery and equipment and 5 to 10 years for furniture and fixtures. Repairs and maintenance expenditures, which do not extend the useful lives of the related assets, are expensed as incurred.
	In the event that facts and circumstances indicate that long-lived assets may be impaired, an evaluation of recoverability is performed. Should such evaluation indicate that there has been an impairment of one or more long-lived assets, the cost basis of such assets would be adjusted accordingly at that time.
	Income Taxes
	Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized and are adjusted when conditions indicate that deferred assets will be realized. Income tax expense (benefit) is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.
	The Company evaluates any uncertain tax positions for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes. In the event recognition of an uncertain tax position is indicated, the Company measures the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. This process of evaluating and estimating uncertain tax positions and tax benefits requires the consideration of many factors, which may require periodic adjustments and which may not accurately forecast actual outcomes. Interest and penalties, if any, related to tax contingencies would be included in income tax expense.
	Loss per Share
	Basic net loss per share is based on the weighted average number of common shares outstanding without consideration of potentially dilutive shares of common stock. There were no shares of preferred stock outstanding with rights to share in the Company’s net income during the years ended December 31, 2014 and 2013. Diluted net income per share is based on the weighted average number of common and potentially dilutive common shares outstanding, when applicable.
	Use of Estimates
	The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives and variable conversion rates, determining a value for shares of Series A Preferred Stock and Series B Convertible Stock issued and certain limited anti-dilution rights granted to George J. Coates as more fully described in Note 16, assigning useful lives to the Company’s property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, estimating a valuation allowance for deferred tax assets, assigning expected lives to, and estimating the rate of forfeitures of, stock options granted and selecting a trading price volatility factor for the Company’s common stock in order to estimate the fair value of the Company’s stock options on the date of grant or other appropriate measurement date. Actual results could differ from those estimates.

Concentrations_of_Credit_and_B

Concentrations of Credit and Business Risk	12 Months Ended
	Dec. 31, 2014
Concentrations of Credit and Business Risk [Abstract]
CONCENTRATIONS OF CREDIT AND BUSINESS RISK	2. CONCENTRATIONS OF CREDIT AND BUSINESS RISK
	The Company maintains cash balances with two financial institutions. Monies on deposit with one of the institutions is currently fully insured by the Federal Deposit Insurance Corporation. Monies on deposit at the other financial institution amounting to $213,000 are invested in a fund that invests in securities with maturities of 60 days or less. At December 31, 2014, approximately 93% of the fund was invested in bank certificates of deposit, asset backed commercial paper and government agency debt securities.
	The Company’s operations are devoted to the development, application and marketing of the CSRV® system technology which was invented by George J. Coates, the Company’s founder, Chairman, Chief Executive Officer, President and controlling stockholder. Development efforts have been conducted continuously during this time. From July 1982 through May 1993, seven U.S. patents as well as a number of foreign patents were issued with respect to the CSRV® system technology. Since inception of the Company in 1988, all aspects of the business have been completely dependent upon the activities of George J. Coates. The loss of George J. Coates’ availability or service due to death, incapacity or otherwise would have a material adverse effect on the Company's business and operations. The Company does not presently have any key-man life insurance in force for Mr. Coates.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2014
Fair Value of Financial Instruments [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	3. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Cash, Other Assets, Accounts Payable and Accrued Liabilities and Other Liabilities
	With the exception of convertible promissory notes, the carrying amount of these items approximates their fair value because of the short term maturity of these instruments. The convertible promissory notes are reported at their estimated fair value, determined as described in more detail in Note 15.
	Limitations
	Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

Licensing_Agreement_and_Deferr

Licensing Agreement and Deferred Licensing Costs	12 Months Ended
	Dec. 31, 2014
Licensing Agreement and Deferred Licensing Costs [Abstract]
LICENSING AGREEMENT AND DEFERRED LICENSING COSTS	4. LICENSING AGREEMENT AND DEFERRED LICENSING COSTS
	The Company holds a manufacturing, use, lease and sale license from George J. Coates and Gregory G. Coates for the CSRV® system technology in the territory defined as the Western Hemisphere (the “License Agreement”). Under the License Agreement, George J. Coates and Gregory G. Coates granted to the Company an exclusive, perpetual, royalty-free, fully paid-up license to the intellectual property that specifically relates to an internal combustion engine that incorporates the CSRV® system technology (the “CSRV® Engine”) and that is currently owned or controlled by them (the “CSRV® Intellectual Property”), plus any CSRV® Intellectual Property that is developed by them during their employment with the Company. In the event of insolvency or bankruptcy of the Company, the licensed rights would terminate and ownership would revert back to George J. Coates and Gregory G. Coates.
	Under the License Agreement, George J. Coates and Gregory G. Coates agreed that they will not grant any Western Hemisphere licenses to any other party with respect to the CSRV® Intellectual Property.
	At December 31, 2014 and 2013 deferred licensing costs, comprised of expenditures for patent costs incurred pursuant to the CSRV® licensing agreement, net of accumulated amortization, amounted to $47,000 and $51,000, respectively. Amortization expense for the years ended December 31, 2014 and 2013 amounted to $4,000 and $4,000, respectively.

Agreements_Assigned_to_Almont_

Agreements Assigned to Almont Energy, Inc.	12 Months Ended
	Dec. 31, 2014
Agreements Assigned To Related Party [Abstract]
AGREEMENTS ASSIGNED TO ALMONT ENERGY, INC.	5. AGREEMENTS ASSIGNED TO ALMONT ENERGY, INC.
	Almont Energy Inc. (“Almont”), a privately held, independent third-party entity based in Alberta, Canada is the assignee of a sublicense which provides for a $5,000,000 license fee to be paid to the Company and covers the use of the CSRV® system technology in the territory of Canada in the oil and gas industry (the “Canadian License”). Almont is also the assignee of a separate research and development agreement (“R&D Agreement”) which requires that Almont pay the remaining balance of an additional $5,000,000 fee to the Company in consideration for the development and delivery of certain prototype engines. The Company completed development of the prototypes in accordance with this agreement at the end of 2007. The R&D Agreement has not been reduced to the form of a signed, written agreement.
	Almont is also the assignee of an escrow agreement (the “Escrow Agreement”) that provides conditional rights to a second sublicense agreement from the Company for the territory of the United States (the “US License”). The US License has been deposited into an escrow account and the grant of the license will not become effective until the conditions for release from escrow are satisfied. The US License provides for a license fee of $50 million.
	The Escrow Agreement requires that Almont, as the assignee, make a payment (“Release Payment”) to the Company equal to the then remaining unpaid balance of the Canadian License licensing fee, the R&D Agreement fee and the down payment of $1,000,000 required under the US License. It is not likely that Almont will be able to make additional payments of the Release Payment until the Company can raise sufficient new working capital to commence production and shipment of Gen Sets to Almont. At December 31, 2014, the remaining balance of the Release Payment due to the Company was $5,847,000.
	In connection with the assignment of the Canadian License and the rights to the US License, Almont has also assumed all of the obligations set forth in the Escrow Agreement, with the following modifications:
		●	The Release Payment Date, as defined in the Escrow Agreement had been extended to March 19, 2014. In order to compensate for the delay caused by the Company’s inability to deliver Gen Sets, the Release Payment due date will be reset as appropriate, once the Company commences its production phase of operations. Provided that Almont remits this entire unpaid balance to the Company by the Release Payment Date, the US License will be released from escrow and granted to Almont. Almont is required to remit to the Company 60% of all monies it raises from future equity or debt transactions, exclusive of proceeds from equipment purchase financing transactions, until the Release Payment is paid in full.
		●	Almont also became obligated to pay the $49 million balance of the US License Fee to the Company. Payment shall be made quarterly in an amount equal to 5% of Almont’s quarterly net profits. In addition, Almont is required to remit a portion of the proceeds it receives from equity or debt transactions, exclusive of equipment financing transactions to the Company until the entire balance of the US License fee is paid in full. However, unless extended by the Company, the entire licensing fee is required to be paid on or before February 19, 2016.
	The Canadian License
	The Canadian License exclusively sublicenses within Canada, the use of the CSRV® system technology for industrial engines designed to generate electrical power. Additional provisions of the Canadian License agreement are as follows:
		●	Sublicensee shall have the exclusive right to use, lease and sell electric power generators designed with the CSRV® system technology within Canada.
		●	Sublicensee will have a specified right of first refusal to market the electric power generators worldwide.
		●	Upon commencement of the production and distribution of the electric power generators, the minimum annual number of generators to be purchased by Sublicensee in order to maintain exclusivity is 120. The Company has temporarily waived this provision due to the delay in delivery of Gen Sets.  In the event Sublicensee fails to purchase the minimum 120 CSRV® generator engines during any year, Sublicensee will automatically lose its exclusivity. In such a case, Sublicensee would retain non-exclusive rights to continue to use and sell the CSRV®generator engines in the territory of Canada. Until otherwise agreed between the parties, the price per generator shall be $159,000.
		●	Sublicensee is required to pay a royalty to the Company equal to 5% of its annual modified gross profit (which has been defined as sales, less cost of sales, plus $400,000).
	All licensed rights under this license agreement related to the CSRV® system technology will remain with the Company.
	The US License
	The US License will, upon Almont satisfying the Release Payment, grant to Almont the right to use, sell and lease within the United States of America, Licensed Products manufactured by the Company which are designed to generate electrical power.  Licensed Products consist of CSRV®Valve Systems, CSRV® Valve Seals, CSRV® Rotary Valve Spheres, CSRV® Valve Components and CSRV® Engines. Almont is also obligated to pay a royalty to the Company equal to 2.5% of its annual modified gross profit (which has been defined as sales, less cost of sales, plus $400,000).
	The manufacture of any Licensed Products by Sublicensee is prohibited.  Sublicensee is required to procure all internal combustion engines incorporating the CSRV® Valve System from the Company or its designee. The license granted to Sublicensee is exclusive within the Territory, provided that Sublicensee satisfies the minimum annual purchase commitment of 120 internal combustion engines incorporating the CSRV® system technology, the Coates Engines and all component parts. The agreement also grants Sublicensee a right of first refusal in the event that the Company negotiates an offer with another third party for a worldwide license to use the Licensed Products for the generation of electrical power.
	The business plan of Almont, which is highly dependent on its ability to raise sufficient additional working capital, is based on its projected assessment of the marketplace demand for industrial generators and projects Gen Set purchases of up to 11,000 CSRV® Units per year over the first 5 years. The Company would not be able to accommodate that demand until it ramps up its production capacity, which would likely require several years, once it enters into large scale production. Almont intends to issue standard purchase orders, issued based on market and customer demand. The Company is unable to confirm any orders until it has sufficient working capital in place to manufacture generators on a large scale. Almont plans to finance its purchases from cash flow and by way of project and/or equipment financing, proceeds from issuance of equity or corporate debt instruments and conventional bank financing.

Proposed_NonExclusive_Distribu

Proposed Non-Exclusive Distribution Sublicense with Renown Power Development, Ltd.	12 Months Ended
	Dec. 31, 2014
Proposed Non-Exclusive Distribution Sublicense With Renown Power Development, Ltd. [Abstract]
PROPOSED NON-EXCLUSIVE DISTRIBUTION SUBLICENSE WITH RENOWN POWER DEVELOPMENT, LTD.	6. PROPOSED NON-EXCLUSIVE DISTRIBUTION SUBLICENSE WITH RENOWN POWER DEVELOPMENT, LTD.
	The Company has been in the process of negotiating the grant of a non-exclusive distribution sublicense to Renown Power Development, Ltd., a China-based sales and distribution company (“Renown”), covering the territory defined as the Western Hemisphere. This sublicense would provide for the payment of licensing fees amounting to US$100 million. The Company has received an initial non-refundable deposit of $500,000 to date. The tentative terms of the agreement would provide that after Renown receives an aggregate of US$10,000,000, it would be required to pay the Company 25% of all funds it receives from any and all sources until the entire US$100 million licensing fee is paid in full. In the event, that Renown completes one or more capital raises aggregating US$300 million or more, the then remaining unpaid balance of the US$100 million licensing fee would become immediately due and payable.
	Subsequent to year-end, the Company consummated this agreement and granted this Sublicense to Renown. This is discussed in more detail in Note 28 – “Subsequent Events,”

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory [Abstract]
INVENTORY	7. INVENTORY
	Inventory at December 31, consisted of the following:
		2014			2013
	Raw materials	$	381,000		$	440,000
	Work-in-process		53,000			59,000
	Finished goods		-			-
	Less: Reserve for obsolescence		(387,000	)		(387,000	)
	Total	$	47,000		$	112,000

License_Deposits

License Deposits	12 Months Ended
	Dec. 31, 2014
License Deposits [Abstract]
LICENSE DEPOSITS	8. LICENSE DEPOSITS
	The current portion of license deposits consists of a $498,000 refundable initial good faith deposit on the tentative sublicense agreement with Renown is discussed in more detail in Note 6 and the $20,000 current portion of a non-refundable deposit on the sublicense agreement with Almont is discussed in more detail in Note 5. The non-current portion of the license deposits primarily consists of the portion of the non-refundable deposit on the sublicense agreement with Almont that will be recognized as sublicensing fee revenue after December 31, 2015.
	The Company is recognizing the Almont sublicense license deposit as revenue on a straight-line basis over the remaining life until 2027 of the last CSRV® technology patent in force, at that date. Sublicensing fee revenue for the years ended December 31, 2014 and 2013 amounted to $19,000 and $19,000, respectively.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	9. PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment at cost, less accumulated depreciation, consists of the following at December 31:
		2014			2013
	Land	$	1,235,000		$	1,235,000
	Building		964,000			964,000
	Building improvements		83,000			83,000
	Machinery and equipment		658,000			658,000
	Furniture and fixtures		39,000			39,000
			2,979,000			2,979,000
	Less:  Accumulated depreciation		(860,000	)		(799,000	)
	Total	$	2,119,000		$	2,180,000
	Depreciation expense amounted to $61,000 and $62,000 for the years ended December 31, 2014 and 2013, respectively.

Mortgage_Loan_Payable

Mortgage Loan Payable	12 Months Ended
	Dec. 31, 2014
Mortgage Loan Payable [Abstract]
MORTGAGE LOAN PAYABLE	10. MORTGAGE LOAN PAYABLE
	The Company has a mortgage loan on the land and building that serves as its headquarters and research and development facility which bears interest at the rate of 7.5% per annum and which matures in July 2015. Interest expense for the years ended December 31, 2014 and 2013 on this mortgage amounted to $121,000 and $114,000, respectively. The loan requires monthly payments of interest, plus $5,000 which is being applied to the principal balance. The remaining principal balance at December 31, 2014 was $1,448,000. The Company will be required to renegotiate the terms of a further extension of the mortgage loan or successfully refinance the property with another mortgage lender, if possible. Failure to do so, could adversely affect the Company’s financial position and results of operations.
	The loan is collateralized by a security interest in all of the Company’s assets, the pledge of five million shares of common stock of the Company owned by George J. Coates, which were deposited into escrow for the benefit of the lender and the personal guarantee of George J. Coates. The Company is not permitted to create or permit any secondary mortgage or similar liens on the property or improvements thereon without prior consent of the lender. Up to $500,000 of the principal balance of the mortgage loan may be prepaid each year without penalty. A prepayment penalty of 2% of the outstanding loan amount would be imposed if the loan is repaid in full at or before maturity unless such prepayment funds are obtained from a permanent mortgage loan with the lender.

Finance_Lease_Obligation

Finance Lease Obligation	12 Months Ended
	Dec. 31, 2014
Finance Lease Obligation [Abstract]
FINANCE LEASE OBLIGATION	11. FINANCE LEASE OBLIGATION
	In August 2013, the Company entered into a sale/leaseback financing arrangement with Paradigm Commercial Capital Group Corp (“Paradigm”) pursuant to which it sold its research and development and manufacturing equipment in consideration for net cash proceeds of $133,000. These cash proceeds were net of a deposit on the lease of $15,000 and transaction costs of $5,000. Under this arrangement, the Company is leasing back the equipment over a 24-month period, with an option to extend the lease for an additional six months. The fixed recurring monthly lease payment amount is $8,000. If the Company does not exercise the six-month extension option, then the parties will negotiate a repurchase price to be paid by the Company for the equipment. If the Company does exercise its option to extend, then ownership of the equipment will automatically revert back to the Company at the end of the option period. The effective interest rate on this lease is 36.6%.
	In accordance with generally accepted accounting principles, this sale/leaseback is required to be accounted for as a financing lease. Under this accounting method, the equipment and accumulated depreciation remains on the Company’s books and records as if the Company still owned the equipment. This accounting treatment is in accordance with ASC 840-40-25-4, Accounting for Sale-Leaseback Transactions. In addition, the discounted present value of the lease payments is recorded as a lease finance obligation. The difference between the gross sales price for the equipment and the net proceeds received amounted to $20,000, which has been recorded as unamortized discount on finance lease obligation. This amount is being amortized to interest expense using the interest method over the 30-month term of the lease, including the option period. The finance lease obligation is secured by all of the equipment included in the sale/leaseback transaction and the personal guaranty of George J. Coates.
	For the years ended December 31, 2014 and 2013, interest expense on this lease amounted to $51,000 and $21,000, respectively, which is included in interest expense in the accompanying statements of operations.

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities at December 31, are as follows:
		2014		2013
	Legal and professional fees	$	1,290,000	$	1,388,000
	Accrued interest expense		374,000		264,000
	General and administrative expenses		194,000		301,000
	Research and development costs		115,000		115,000
	Accrued compensation and benefits		10,000		196,000
	Total	$	1,983,000	$	2,264,000

Promissory_Notes_to_Related_Pa

Promissory Notes to Related Parties	12 Months Ended
	Dec. 31, 2014
Promissory Notes To Related Parties [Abstract]
PROMISSORY NOTES TO RELATED PARTIES	13. PROMISSORY NOTES TO RELATED PARTIES
	Promissory Notes Issued to George J. Coates
	During the year ended December 31, 2013, the Company issued, in a series of transactions, promissory notes to George J. Coates and received cash proceeds of $105,000. During the years ended December 31, 2014 and 2013 the Company repaid promissory notes to George J. Coates in the aggregate principal amount of $200,000 and $67,000, respectively. The promissory notes are payable on demand and provide for interest at the rate of 17% per annum, compounded monthly.
	During the period from March 28, 1991 through April 15, 1994, Mr. Coates made cash outlays of his own personal funds to acquire the Company’s headquarters, research and development and warehouse facility amounting to $950,000. Mr. Coates contributed this property to the Company and did not receive any consideration for this contribution. At that time, the $950,000 purchase price was added to the Company’s additional paid-in capital. Mr. Coates has been anticipating that these monies would be repaid to him at such time that the Company had sufficient working capital for this purpose. On April 28, 2014, the board of directors adopted a resolution to make a compensatory award of $950,000 in the form of a non-interest bearing promissory note payable on demand due to Mr. Coates. The intent of this resolution was to compensate Mr. Coates for his lost benefits of ownership of the Company’s headquarters, research and development and warehouse facility subsequent to the date he contributed this property. Mr. Coates offered to apply this amount towards the purchase of additional shares of the Company’s common stock.
	On April 29, 2014, the board of directors adopted another resolution to convert this non-interest bearing demand loan in the amount of $950,000, along with $50,000 of interest bearing, 17% promissory notes due to Mr. Coates into shares of the Company’s common stock, bringing the total amount converted to $1 million. The conversion price per share was determined to be equal to the closing trading price of the common stock on April 29, 2014. The closing trading price on that date was $0.0252 per share. As a result of this resolution, 39,682,540 restricted shares of common stock were issued to Mr. Coates as of April 29, 2014. As a result of the conversion of the promissory notes into shares of common stock, stockholders experienced a dilution. The percentage of the Company owned by non-affiliate shareholders decreased from 32.9% to 29.5% of the outstanding common stock of the Company. The net effect on the Company’s balance sheet was to decrease current liabilities by $50,000 and decrease stockholders’ deficit by the same amount.
	In addition, during May 2014, by mutual consent between Mr. Coates and the Company, the remaining $370,000 principal amount of the promissory notes due to Mr. Coates was converted into restricted shares of common stock of the Company at the closing price per share of $0.029 on May 30, 2014. These promissory notes arose from cash lent to the Company for working capital purposes from Mr. Coates’ personal funds. As a result, the Company issued 12,749,162 shares of restricted common stock to Mr. Coates. In September 2014, by mutual consent between Mr. Coates and the Company, a $200,000 portion of the transaction converting promissory notes to common stock was rescinded. Accordingly, 6,896,552 shares of common stock were returned, cancelled and restored to authorized, unissued status and $200,000 of promissory notes due to Mr. Coates was reinstated as a liability. The net result of this transaction and the partial rescission of this transaction was to reduce current liabilities by $170,000 and reduce stockholders’ deficiency by the same amount. In addition, annual interest expense will be reduced by approximately $29,000.
	Promissory Note Issued to Gregory G. Coates
	During the period from August 21, 1995 to February 14, 1996, Gregory G. Coates, son of George J. Coates, President, Technology Division and director, in a series of payments, made cash outlays from his own personal funds on behalf of the Company, in an amount which aggregated $1,462,000 to provide needed working capital to the Company in order for it to continue its operations. Gregory G. Coates contributed these funds to the Company and did not receive any consideration for this contribution. At that time, the $1,462,000 of cash outlays was added to the Company’s additional paid-in capital. Gregory G. Coates has been anticipating that these monies would be repaid to him at such time that the Company had sufficient working capital for this purpose. Gregory G. Coates has requested that this amount of additional paid-in capital be converted into a non-interest bearing promissory note. On April 28, 2014, the board of directors adopted a resolution to convert $1,462,000 of additional paid-in capital of the Company into a non-interest bearing promissory note payable on demand, due to Gregory G. Coates. As a result, the Company’s additional paid-in capital decreased by $1,462,000 and current liabilities increased by $1,462,000.
	Promissory Notes Issued to Bernadette Coates
	During the year ended December 31, 2013 the Company issued, in a series of transactions, promissory notes to Bernadette Coates, spouse of George J. Coates and received cash proceeds of $68,000. During the years ended December 31, 2014 and 2013 the Company repaid promissory notes in the aggregate principal amount of $80,000 and $10,000, respectively. The promissory notes were payable on demand and provided for interest at the rate of 17% per annum, compounded monthly.
	For the years ended December 31, 2014 and 2013, aggregate interest expense on all promissory notes to related parties amounted to $112,000 and $130,000, respectively. Unpaid accrued interest on these promissory notes amounting to $342,000 is included in accounts payable and accrued liabilities in the accompanying balance sheet at December 31, 2014.

10_Convertible_Note_to_Related

10% Convertible Note to Related Party	12 Months Ended
	Dec. 31, 2014
10% Note to Related Party [Abstract]
10% NOTE TO RELATED PARTY	14. 10% CONVERTIBLE NOTE TO RELATED PARTY
	In June 2014, a 10% promissory note with a balance due of $17,000, including accrued interest thereon, held by Dr. Michael J. Suchar, director, was converted into 612,664 restricted shares of common stock at a conversion price equal to the closing price of the common stock on the date of conversion of $0.0285 per share.

Convertible_Promissory_Notes_a

Convertible Promissory Notes and Embedded Derivative Liability	12 Months Ended
	Dec. 31, 2014
Convertible Promissory Notes and Embedded Derivative Liability [Abstract]
CONVERTIBLE PROMISSORY NOTES AND EMBEDDED DERIVATIVE LIABILITY	15. CONVERTIBLE PROMISSORY NOTES AND EMBEDDED DERIVATIVE LIABILITY
	From time to time, the Company issues convertible promissory notes. The net proceeds from these transactions are used for general working capital purposes. During the years ended December 31, 2014 and 2013, $996,000 and $398,000, respectively, of convertible promissory notes were issued. The notes may be converted into unregistered shares of the Company’s common stock at a discount ranging from 30% to 42% of the defined trading price of the common stock on the date of conversion. The defined trading prices are based on the trading price of the stock during a defined period ranging from ten to twenty-five trading days immediately preceding the date of conversion. The conversion rate discount establishes a beneficial conversion feature (“BCF”) or unamortized discount which is required to be valued and accreted to interest expense over the six-month period until the conversion of the notes into restricted shares of common stock is permitted. In addition, the conversion formula meets the conditions that require accounting for them as derivative liability instruments.
	All of the convertible notes become convertible, in whole, or in part, beginning on the six month anniversary of the issuance date and may be prepaid at the option of the Company, generally with a prepayment penalty of from 25% to 50% of the principal amount of the convertible note at any time prior to becoming eligible for conversion.
	One convertible promissory note with a balance of $132,000 is convertible in monthly installments. The Company may elect, at its option to repay each monthly installment in whole, or in part, in cash without penalty. The amount of each installment not paid in cash is converted into shares of the Company’s common stock. This convertible note also requires that the conversion price be re-measured 23 trading days after the conversion shares are originally delivered. If the re-measured conversion price is lower, then the Company is required to issue additional conversion shares to the noteholder.
	In accordance with GAAP, the estimated fair value of the embedded derivative liability related to the Convertible Notes is required to be remeasured at each balance sheet date. The estimated fair value of the embedded derivative liabilities related to promissory notes outstanding was measured as the aggregate estimated fair value, based on Level 2 inputs, which included the average of the quoted daily yield curve rates on six-month and one-year treasury securities and the calculated 12-month historical volatility rate on the Company’s common stock.
	The embedded derivative liability arises because, based on historical trading patterns of the Company’s stock, the formula for determining the Conversion Rate is expected to result in a different Conversion Rate than the closing price of the stock on the actual date of conversion (hereinafter referred to as the “Variable Conversion Rate Differential”). The estimated fair values of the derivative liabilities have been calculated based on a Black-Scholes option pricing model.
	The following table presents the details of the convertible promissory notes outstanding at December 31, 2014 and 2013, including the balance of the unamortized discount and the amount of the embedded derivative liability, where applicable:
			Principal Amount													Unamortized Discount				Embedded
																				Derivative Liability
	Date Issued		December 31, 2014		December 31, 2013		Nominal Interest Rate			Effective Interest Rate(1)			Conversion Price Discount from Defined Trading Price			December 31, 2014		December 31, 2013		December 31, 2014		December 31, 2013
	12/16/14		$	28,000		N/A		12	%		55	%		40	%	$	8,000		N/A	$	31,000		N/A
	12/5/14			53,000		N/A		8	%		160	%		39	%		42,000		N/A		20,000		N/A
	11/25/14			52,000		N/A		9.75	%		91	%		30	%		24,000		N/A		41,000		N/A
	11/14/14			40,000		N/A		8	%		139	%		32.5	%		30,000		N/A		54,000		N/A
	10/2/14			40,000		N/A		8	%		113	%		35	%		16,000		N/A		43,000		N/A
	9/29/14			53,000		N/A		8	%		118	%		39	%		29,000		N/A		20,000		N/A
	9/3/14			39,000		N/A		12	%		139	%		40	%		15,000		N/A		38,000		N/A
	8/29/14			53,000		N/A		8	%		105	%		39	%		13,000		N/A		17,000		N/A
	8/8/14			52,000		N/A		9.75	%		72	%		30	%		5,000		N/A		41,000		N/A
	7/28/14			30,000		N/A		12	%		156	%		30	%		6,000		N/A		25,000		N/A
	7/9/14			83,000		N/A		8	%		120	%		39	%		5,000		N/A		15,000		N/A
	7/8/14			50,000		N/A		5	%		106	%		37	%		2,000		N/A		31,000		N/A
	6/12/14			47,000		N/A		8	%		147	%		40	%		-		N/A		46,000		N/A
	4/16/14			25,000		N/A		12	%		147	%		30	%		-		N/A		17,000		N/A
	4/16/14			24,000		N/A		12	%		175	%		40	%		-		N/A		15,000		N/A
	4/2/14			27,000		N/A		9.75	%		71	%		30	%		-		N/A		22,000		N/A
	12/11/13			-		28,000		10	%		134	%		42	%		N/A		22,000		N/A		43,000
	12/10/13			-		28,000		12	%		117	%		40	%		N/A		19,000		N/A		45,000
	12/9/13			-		28,000		10	%		134	%		42	%		N/A		22,000		N/A		43,000
	11/27/13			-		32,000		8	%		133	%		39	%		N/A		25,000		N/A		33,000
	10/11/13			-		47,000		8	%		147	%		39	%		N/A		31,000		N/A		48,000
	8/14/13			-		28,000		12	%		147	%		40	%		N/A		14,000		N/A		45,000
	8/8/13			-		53,000		8	%		147	%		39	%		N/A		14,000		N/A		53,000
	6/4/13			-		28,000		12	%		92	%		40	%		N/A		-		N/A		45,000
	3/21/13			-		-		12	%		76	%		40	%		N/A		-		N/A		12,000
			$	696,000	$	272,000										$	195,000	$	147,000	$	476,000	$	367,000
		-1	The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.
	In a series of transactions, during the year ended December 31, 2014, convertible promissory notes with an aggregate principal balance of $627,000, including accrued interest thereon were converted into 48,251,621 unregistered shares of common stock.
	In a series of transactions, during the year ended December 31, 2013, convertible promissory notes with an aggregate principal balance of $271,000, including accrued interest thereon were converted into 13,718,349 unregistered shares of common stock.
	Other expense resulting from the increase in the estimated fair value of the embedded derivative liabilities amounted to ($104,000) and ($210,000) for the years ended December 31, 2014 and 2013, respectively. These amounts are included in the accompanying statements of operations as Increase in estimated fair value of embedded derivative liabilities. Interest expense resulting from accretion of the unamortized discount for the years ended December 31, 2014 and 2013 amounted to $697,000 and $283,000, respectively.
	At December 31, 2014, the Company had reserved 263,703,000 shares of its unissued common stock for conversion of convertible promissory notes.
	The Company made the private placement of these securities in reliance upon Section 4(2) of the Securities Act of 1933, as amended (the “Act”), Rule 506 of Regulation D, and the rules and regulations promulgated thereunder, and/or upon any other exemption from the registration requirements of the Act, as applicable.

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2014
Capital Stock [Abstract]
CAPITAL STOCK	16. CAPITAL STOCK
	Common Stock
	The Company’s common stock is traded on OTC Pink Sheets. Investors can find real-time quotes and market information for the Company at www.otcmarkets.com market system under the ticker symbol COTE. The Company is authorized to issue up to 1,000,000,000 shares of common stock, par value, $0.0001 per share (the “Common Stock”).
	Pursuant to anti-dilution provisions which became effective January 2012, Mr. Coates was awarded one share of restricted common stock for each new share of stock issued to any individual or entity that was not a member of, or controlled by, the Coates Family. On August 30, 2013, these anti-dilution provisions were canceled and Mr. Coates voluntarily returned all shares of common stock awarded to him under these provisions.
	The following common stock transactions occurred during the year ended December 31, 2014:
		●	In a series of transactions, the Company made private sales, pursuant to stock purchase agreements of 16,456,076 unregistered shares of its common stock and 16,456,076 common stock warrants to purchase one restricted share of its common stock at exercise prices ranging from $0.02 to $0.04 per share in consideration for $515,000 received from the son of Dr. Richard W. Evans, a director. The proceeds were used for general working capital.
		●	In a series of transactions, the Company issued 4,403,403 registered shares of common stock to Dutchess Opportunity Fund II, LP under an equity line of credit in consideration for $162,000. The proceeds were used for general working capital.
		●	In two transactions during April and May, 17% promissory notes due to George J. Coates having a principal balance of $420,000 were converted, by mutual consent, into 14,733,289 restricted shares of common stock at an average price per share of $0.0285 which was equal to the closing price of the Company’s common stock on the dates of conversion. In August 2014, by mutual consent between the Company and George J. Coates, the conversion of $200,000 of these 17% promissory notes was rescinded. Accordingly, 6,896,552 of the shares issued to Mr. Coates were returned for cancellation and restored to authorized, unissued status and the $200,000 principal amount of the promissory note was reinstated.
		●	A non-interest bearing promissory note due to George J. Coates in the principal amount of $950,000 was converted, by mutual consent, into 37,698,413 restricted shares of common stock at an average price per share of $0.0252 which was equal to the closing price of the Company’s common stock on the date of conversion.
		●	A 10% promissory note with a balance of $17,000 due to Michael J. Suchar, director, was converted, by mutual consent, into 612,664 restricted shares of common stock at an average price per share of $0.0285 which was equal to the closing price of the Company’s common stock on the date of conversion.
		●	In a series of transactions, convertible promissory notes, including accrued interest thereon aggregating $627,000 were converted into 48,251,621 unregistered shares of the Company’s common stock,
		●	The Company received proceeds of $10,000 from the son of Richard W. Evans, a director for the exercise of stock purchase warrants with an exercise price of $0.02 per share and issued 500,000 unregistered shares of its common stock. The proceeds were used for general working capital.
	The following common stock transactions occurred during the year ended December 31, 2013:
		●	In a series of transactions, the Company made private sales, pursuant to stock purchase agreements of 4,666,666 unregistered shares of its common stock and 5,566,668 common stock warrants to purchase one share of its common stock at exercise prices ranging from $0.015 to of $0.04 per share in consideration for $125,000 received from the son of Richard W. Evans, a director. The proceeds were used for general working capital.
		●	In a series of transactions, the Company issued 3,618,676 registered shares of its common stock to Dutchess Opportunity Fund II, LP under an equity line of credit in consideration for $156,000. The proceeds were used for general working capital.
		●	In a series of transactions, the Company issued 14,142,085 unregistered shares of its common stock to George J. Coates for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares, based on the closing trading price of the stock on the dates of the issuances was $420,000. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to authorized, unissued status.
		●	In January 2013, the Company issued 20,895,046 unregistered shares of its common stock to George J. Coates in satisfaction of a deferred compensation liability consisting of 20,275,046 shares for anti-dilution protection for the year ended December 31, 2012 and a 620,000 share stock award originally granted in 2011. The value of these shares, based on the closing trading price on the dates of the anti-dilution or the date of the stock award was $1,761,000, of which $1,674,000 and $87,000 was charged to stock compensation expense during the years ended December 31, 2012 and 2011, respectively. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to authorized, unissued status.
		●	As discussed in more detail in Note 15, in a series of transactions, convertible promissory notes with an aggregate principal balance, including accrued interest of $271,000 were converted into 13,718,349 unregistered shares of the Company’s common stock.
		●	The Company received proceeds of $10,000 from the son of Richard W. Evans, a director for the exercise of stock purchase warrants with an exercise price of $0.015 per share and issued 666,667 unregistered shares of its common stock. The proceeds were used for general working capital.
	At December 31, 2014, the Company had reserved 312,047,911 shares of its common stock to cover the potential conversion of convertible securities and exercise of stock options and warrants.
	Preferred Stock and anti-dilution rights
	The Company is authorized to issue 100,000,000 shares of preferred stock, par value, $0.001 per share (the “Preferred Stock”). The Company may issue any class of the Preferred Stock in any series. The board is authorized to establish and designate series, and to fix the number of shares included in each such series and the relative rights, preferences and limitations as between series, provided that, if the stated dividends and amounts payable on liquidation are not paid in full, the shares of all series of the same class shall share ratably in the payment of dividends including accumulations, if any, in accordance with the sums which would be payable on such shares if all dividends were declared and paid in full, and in any distribution of assets other than by way of dividends in accordance with the sums which would be payable on such distribution if all sums payable were discharged in full. Shares of each such series when issued shall be designated to distinguish the shares of each series from shares of all other series.
	There are two series of Preferred Stock that have been designated to date from the total 100,000,000 authorized shares of Preferred Stock. These are as follows:
		●	Series A Preferred Stock, par value $0.001 per share (“Series A”), 1,000,000 shares designated and 50,000 and 141,473 shares issued and outstanding as of December 31, 2014 and 2013, respectively. Shares of Series A entitle the holder to 10,000 votes per share on all matters brought before the shareholders for a vote. These shares are not entitled to receive dividends or share in distributions of capital and have no liquidation preference. All outstanding shares of Series A are owned by George. J. Coates.
	In order to enable the Company to raise needed working capital, an anti-dilution arrangement was established which authorized the issuance of shares of Series A to George J. Coates to restore the Coates Family’s voting percentage upon any future issuance of new shares of the Company’s common stock as a result of a sale or conversion of securities into common stock, provided, however, that no anti-dilution protection shall be available in connection with public offerings of the Company’s securities.
	During the period from January 1, 2014 to July 2, 2014, and during the year ended December 31, 2013, 40,191 and 68,590 shares, respectively, of Series A were granted and issued to George J. Coates pursuant to this anti-dilution agreement. On July 3, 2014 all of the 181,664 shares of Series A previously issued to George J. Coates were converted into shares of Series B Convertible Preferred Stock, $0.001 par value per share (“Series B”), as more fully explained below. All such converted shares of Series A were cancelled and restored to authorized, unissued status. At the same time, the aforementioned anti-dilution protection for Mr. Coates, pursuant to which shares of Series A may be issued, was cancelled and replaced with a new anti-dilution protection arrangement which involves the issuance of shares of Series B as more fully explained below. On August 1, 2014, 50,000 shares of Series A were issued to George J. Coates as an inducement to him to consider future offers from investors to acquire substantial ownership interests in the Company as a means of raising substantial new working capital for the Company. At December 31, 2014, Mr. Coates held all 50,000 shares of Series A outstanding, which entitle him to 500 million votes in addition to his voting rights from the shares of common stock and the shares of Series B he holds.
	Each issuance of shares of Series A to George J. Coates did not have any effect on the share of dividends or liquidation value of the holders of the Company’s common stock. However, the voting rights of the holders of the Company’s common stock are diluted with each issuance.
	In 2014, the Company arranged for an independent professional services firm to determine the estimated fair value of the shares of Series A provided to Mr. Coates. Based on this estimated valuation, the aggregate estimated fair value of the 50,000 shares of Series A issued to Mr. Coates on August 1, 2014, was $69,000, or $1.38 per share. Total non-cash, stock-based compensation expense from the grant of shares of Series A to Mr. Coates, including the shares converted to Series B for the years ended December 31, 2014 and 2013, amounted to $169,000 and $170,000, respectively. This amount is included in stock-based compensation expense in the accompanying statements of operations.
		●	Series B Convertible Preferred Stock, par value $0.001 per share, 1,000,000 shares designated and 585,502 and -0- shares issued and outstanding as of December 31, 2014 and 2013, respectively. Shares of Series B do not earn any dividends and may be converted at the option of the holder at any time beginning on the second annual anniversary date after the date of issuance into 1,000 unregistered shares of the Company’s common stock. Holders of the Series B are entitled to one thousand votes per share held on all matters brought before the shareholders for a vote.
			In the event that either (i) the Company enters into an underwriting agreement for a secondary public offering of securities, or (ii) a change in control of the Company is consummated representing 50% more of the then outstanding shares of Company’s common stock, plus the number of shares of common stock into which any convertible preferred stock is convertible, regardless of whether or not such shares are otherwise eligible for conversion, then the Series B may be immediately converted at the option of the holder into restricted shares of the Company’s common stock.
	On July 3, 2014, the board of directors consented to (i) the conversion of all of the 181,664 shares of Series A held by George J. Coates into shares of Series B at a conversion rate of one share of Series B for each share of Series A, (ii) an anti-dilution award of an additional 75,000 shares of Series B to Mr. Coates; and (iii) a modified anti-dilution plan, effective as of July 3, 2014 (the “Modified Plan”) for George J. Coates.
	The anti-dilution award of an additional 75,000 shares of Series B to Mr. Coates was determined to be the number of shares of Series B required to restore Mr. Coates’ ownership percentage of outstanding common stock on a pro forma basis to 78%, assuming all of the Series B shares were converted into common stock. The ownership percentage of 78% represents the percentage of outstanding common stock that Mr. Coates originally held at December 31, 2002.
	Under the Modified Plan, for each new share of common stock issued by the Company to non-Coates family members in the future, additional shares of Series B will be issued to Mr. Coates equal to that number of shares of Series B required to maintain his ownership percentage of outstanding shares of common stock outstanding on a pro forma basis, at 78%.
	These anti-dilution provisions do not apply to new shares of common stock issued in connection with exercises of employee stock options, a secondary public offering of the Company’s securities or a merger or acquisition.
	On July 28, 2014, the board of directors consented to an anti-dilution program which provides that shares of Series B be issued to Gregory G. Coates whenever new shares of common stock are issued to non-Coates family members in order to maintain his ownership percentage of common stock at 5.31% of the pro forma number of shares of common stock outstanding, assuming all shares of Series B were converted to common stock. This was his percentage ownership of common stock at December 31, 2002.
	On July 28, 2014, the board of directors consented to an anti-dilution program which provides that shares of Series B be issued to Barry C. Kaye whenever new shares of common stock are issued to non-Coates family members in order to maintain his ownership percentage of common stock at 0.04157% of the pro forma number of shares of common stock outstanding, assuming all shares of Series B were converted to common stock. This was the weighted average percentage ownership of common stock he purchased, based on the number of shares of common stock outstanding on each date he acquired additional shares of common stock.
	The issuance of these shares of Series B to Gregory G. Coates and Barry C. Kaye triggered the issuance of an additional 115,006 shares of Series B to George J. Coates, in accordance with the anti-dilution program in effect for George J. Coates.
	Under this new anti-dilution Plan, for each new share of common stock issued by the Company to non-Coates family members in the future, additional shares of Series B will be issued to Gregory G. Coates and Barry C. Kaye equal to that number of shares of Series B required to maintain their ownership percentage of outstanding shares of common stock outstanding on a pro forma basis, at 5.31% and 0.04157%, respectively.
	As a result of the new anti-dilution arrangements put into place during 2014, the number of shares of Series B outstanding at December 31, 2014 totaled 585,502 consisting of 541,933, 40,593 and 2,976 shares held by George J. Coates, Gregory G. Coates and Barry C. Kaye, respectively.
	In 2014, the Company arranged for an independent professional services firm to determine the estimated fair value of the shares of Series B. Based on this estimated valuation, the aggregate estimated fair value of the 585,502 shares of Series B was $8,721,000, which was included in stock-based compensation expense in the accompanying statement of operations for the year ended December 31, 2014.
	In the event that all of the 585,502 shares of Series B outstanding were converted, once the conversion restrictions lapse, an additional 585,502,000 new unregistered shares of common stock would be issued. On a pro forma basis, based on the number of shares of common stock outstanding at December 31, 2014, this would dilute the ownership percentage of non-affiliated stockholders from 35.7% to 15.3%.
	To the extent that additional shares of Series B are issued under the anti-dilution plan, the non-affiliated stockholders’ percentage ownership of the Company would be further diluted.

Unearned_Revenue

Unearned Revenue	12 Months Ended
	Dec. 31, 2014
Unearned Revenue [Abstract]
UNEARNED REVENUE	17. UNEARNED REVENUE
	The Company has received a non-refundable deposit from Almont in connection with its orders for natural gas fueled electric power CSRV® engine generators. The $19,000 unused balance of these deposited funds is included in unearned revenue in the accompanying balance sheets at December 31, 2014 and 2013.

Sublicensing_Fee_Revenue

Sublicensing Fee Revenue	12 Months Ended
	Dec. 31, 2014
Sublicensing Fee Revenue [Abstract]
SUBLICENSING FEE REVENUE	18. SUBLICENSING FEE REVENUE
	Sublicensing fee revenue for the years ended December 31, 2014 and 2013, amounted to $19,000 and $19,000, respectively. The Company is recognizing the license deposit of $300,000 on the Canadian Licensee as revenue on a straight-line basis over the approximate remaining life until 2027 of the last CSRV® technology patent in force.

Employee_Compensation_and_Bene

Employee Compensation and Benefits	12 Months Ended
	Dec. 31, 2014
Employee Compensation and Benefits [Abstract]
EMPLOYEE COMPENSATION AND BENEFITS	19. EMPLOYEE COMPENSATION AND BENEFITS
	Employee Compensation and benefits for the years ended December 31, 2014 and 2013, amounted to $10,401,000 and $1,047,000, respectively. This was comprised of non-cash stock-based compensation expense of $10,174,000 and $614,000 for the years ended December 31, 2014 and 2013, respectively. The increase in 2014 primarily resulted from charging to expense, the estimated fair value of shares of Series B Convertible Preferred Stock issued to key executives for anti-dilution. The other component of employee compensation and benefits was for salaries, wages and employee benefits, which amounted to $227,000 and 433,000 for the years ended December 31, 2014 and 2013, respectively. The decrease in 2014 was due to an increase in the portion of compensation and benefits allocated to research and development expenses to $401,000 in 2014 from $237,000 in 2013 and a reduction in payroll taxes and certain employee benefit costs. Included in compensation and benefits for 2014 and 2013 was unpaid salaries for George J. Coates and Bernadette Coates totaling $317,000 and $288,000, for the years ended December 31, 2014 and 2013, respectively, payment of which has been voluntarily deferred until such time that the Company has sufficient working capital.

Income_Loss_Per_Share

Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2014
Income (Loss) Per Share [Abstract]
INCOME (LOSS) PER SHARE	20. INCOME (LOSS) PER SHARE
	At December 31, 2014, the Company had 176,919,302 shares of common stock potentially issuable upon assumed conversion of:
	Description	Number of Underlying Shares of Common Stock		Exercise Price			Number Vested		Number Non-Vested
	Common stock options		703,000	$	0.028			-		703,000
	Common stock options		100,000		0.042			100,000		-
	Common stock options		5,607,000		0.06			5,607,000		-
	Common stock options		1,800,000		0.24			1,800,000		-
	Common stock options		2,000,000		0.25			2,000,000		-
	Common stock options		50,000		0.39			50,000		-
	Common stock options		360,000		0.4			360,000		-
	Common stock options		100,000		0.43			100,000		-
	Common stock options		1,750,000		0.44			1,750,000		-
	Common stock options		30,000		1			30,000		-
	Common stock warrants		1,750,000		0.02			N/A		N/A
	Common stock warrants		666,667		0.0225			N/A		N/A
	Common stock warrants		2,127,660		0.0235			N/A		N/A
	Common stock warrants		5,000,000		0.025			N/A		N/A
	Common stock warrants		1,739,130		0.02875			N/A		N/A
	Common stock warrants		333,333		0.03			N/A		N/A
	Common stock warrants		2,714,287		0.035			N/A		N/A
	Common stock warrants		7,125,000		0.04			N/A		N/A
	Common stock warrants		333,333		0.045			N/A		N/A
	Common stock warrants		400,000		0.05			N/A		N/A
	Common stock warrants		2,181,819		0.055			N/A		N/A
	Common stock warrants		171,428		0.057			N/A		N/A
	Common stock warrants		285,714		0.0581			N/A		N/A
	Common stock warrants		428,571		0.0585			N/A		N/A
	Common stock warrants		2,000,000		0.06			N/A		N/A
	Common stock warrants		4,269,838		0.0625			N/A		N/A
	Common stock warrants		333,333		0.0675			N/A		N/A
	Common stock warrants		571,429		0.07			N/A		N/A
	Common stock warrants		666,666		0.09			N/A		N/A
	Common stock warrants		416,667		0.12			N/A		N/A
	Common stock warrants		1,200,000		0.25			N/A		N/A
	Common stock warrants		833,333		0.27			N/A		N/A
	Common stock warrants		153,846		0.325			N/A		N/A
	Common stock warrants		142,857		0.35			N/A		N/A
	Convertible promissory notes		128,574,391		(1	)		N/A		N/A
	Total		176,919,302
	-1	The principal amount of convertible promissory notes outstanding at December 31, 2014, was $696,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading prices of the common stock over a defined number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2014.
	At December 31, 2013, the Company had 45,970,314 shares of common stock potentially issuable upon assumed conversion of:
	Description	Number of Underlying Shares of Common Stock		Exercise			Number Vested		Number Non-Vested
				Price
	Common stock options		100,000	$	0.042			-		100,000
	Common stock options		5,607,000		0.06			5,607,000		-
	Common stock options		1,800,000		0.24			1,800,000		-
	Common stock options		2,000,000		0.25			2,000,000		-
	Common stock options		50,000		0.39			50,000		-
	Common stock options		360,000		0.4			360,000		-
	Common stock options		100,000		0.43			100,000		-
	Common stock options		1,750,000		0.44			1,750,000		-
	Common stock options		30,000		1			30,000		-
	Common stock warrants		500,000		0.02			N/A		N/A
	Common stock warrants		666,667		0.0225			N/A		N/A
	Common stock warrants		1,000,000		0.025			N/A		N/A
	Common stock warrants		333,333		0.03			N/A		N/A
	Common stock warrants		2,000,001		0.035			N/A		N/A
	Common stock warrants		500,000		0.04			N/A		N/A
	Common stock warrants		333,333		0.045			N/A		N/A
	Common stock warrants		400,000		0.05			N/A		N/A
	Common stock warrants		2,181,819		0.055			N/A		N/A
	Common stock warrants		2,000,000		0.06			N/A		N/A
	Common stock warrants		4,269,838		0.0625			N/A		N/A
	Common stock warrants		571,429		0.07			N/A		N/A
Common stock warrants		666,666		0.09			N/A		N/A
Common stock warrants		416,667		0.12			N/A		N/A
Common stock warrants		1,200,000		0.25			N/A		N/A
Common stock warrants		833,333		0.27			N/A		N/A
Common stock warrants		333,333		0.3			N/A		N/A
Common stock warrants		153,846		0.325			N/A		N/A
Common stock warrants		1,028,570		0.35			N/A		N/A
$10,000, 10% Convertible promissory note to related party		22,222		0.45			N/A		N/A
Convertible promissory notes		14,762,257		(1	)		N/A		N/A
Total		45,970,314
-1	The principal amount of convertible promissory notes outstanding at December 31, 2013, was $272,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading prices of the common stock over a defined number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.
For the years ended December 31, 2014 and 2013, none of the potentially issuable shares of common stock were assumed to be converted because the Company incurred a net loss in those years and the effect of including them in the calculation would have been anti-dilutive.

Stock_Options

Stock Options	12 Months Ended
	Dec. 31, 2014
Stock Options [Abstract]
STOCK OPTIONS	21. STOCK OPTIONS
	The Company’s 2006 Stock Option and Incentive Plan (the “Stock Plan”) was adopted by the Company’s board in October 2006. In September 2007, the Stock Plan, by consent of George J. Coates, majority shareholder, was adopted by our shareholders. The Stock Plan provides for the grant of stock-based awards to employees, officers and directors of, and consultants or advisors to, the Company and its subsidiaries, if any. Under the Stock Plan, the Company may grant options that are intended to qualify as incentive stock options within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (“ISO’s”), options not intended to qualify as incentive stock options (“non-statutory options”), restricted stock and other stock-based awards. ISO’s may be granted only to employees of the Company. A total of 12,500,000 shares of common stock may be issued upon the exercise of options or other awards granted under the Stock Plan. The maximum number of shares with respect to which awards may be granted during any one year to any employee under the Stock Plan shall not exceed 25% of the 12,500,000 shares of common stock covered by the Stock Plan. At December 31, 2014, all of the shares of common stock authorized under the Stock Plan had been granted and no further grants may be awarded thereunder.
	The Company established a 2014 Stock Option and Incentive Plan (the “2014 Stock Plan”) which was adopted by the Company’s board on May 30, 2014. Subsequent to year end on March 2, 2015, the 2014 Stock Plan, by consent of George J. Coates, majority shareholder, was adopted by our shareholders. The 2014 Stock Plan provides for the grant of stock-based awards to employees, officers and directors of, and consultants or advisors to, the Company and its subsidiaries, if any. Under the 2014 Stock Plan, the Company may grant ISO’s, non-statutory options, restricted stock and other stock-based awards. ISO’s may be granted only to employees of the Company. A total of 50,000,000 shares of common stock may be issued upon the exercise of options or other awards granted under the 2014 Stock Plan. The maximum number of shares with respect to which awards may be granted during any one year to any employee under the 2014 Stock Plan shall not exceed 25% of the 50,000,000 shares of common stock covered by the 2014 Stock Plan. At December 31, 2014, none of the shares of common stock authorized under the 2014 Stock Plan had been granted as stock options or awarded.
	The Stock Plan and the 2014 Stock Plan (the “Stock Plans”) are administered by the board and the Compensation Committee. Subject to the provisions of the Stock Plans, the board and the Compensation Committee each has the authority to select the persons to whom awards are granted and determine the terms of each award, including the number of shares of common stock subject to the award. Payment of the exercise price of an award may be made in cash, in a “cashless exercise” through a broker, or if the applicable stock option agreement permits, shares of common stock, or by any other method approved by the board or Compensation Committee. Unless otherwise permitted by the Company, awards are not assignable or transferable except by will or the laws of descent and distribution.
	Upon the consummation of an acquisition of the business of the Company, by merger or otherwise, the board shall, as to outstanding awards (on the same basis or on different bases as the board shall specify), make appropriate provision for the continuation of such awards by the Company or the assumption of such awards by the surviving or acquiring entity and by substituting on an equitable basis for the shares then subject to such awards either (a) the consideration payable with respect to the outstanding shares of common stock in connection with the acquisition, (b) shares of stock of the surviving or acquiring corporation, or (c) such other securities or other consideration as the board deems appropriate, the fair market value of which (as determined by the board in its sole discretion) shall not materially differ from the fair market value of the shares of common stock subject to such awards immediately preceding the acquisition. In addition to, or in lieu of the foregoing, with respect to outstanding stock options, the board may, on the same basis or on different bases as the board shall specify, upon written notice to the affected optionees, provide that one or more options then outstanding must be exercised, in whole or in part, within a specified number of days of the date of such notice, at the end of which period such options shall terminate, or provide that one or more options then outstanding, in whole or in part, shall be terminated in exchange for a cash payment equal to the excess of the fair market value (as determined by the board in its sole discretion) for the shares subject to such stock options over the exercise price thereof. Unless otherwise determined by the board (on the same basis or on different bases as the board shall specify), any repurchase rights or other rights of the Company that relate to a stock option or other award shall continue to apply to consideration, including cash, that has been substituted, assumed or amended for a stock option or other award pursuant to these provisions. The Company may hold in escrow all or any portion of any such consideration in order to effectuate any continuing restrictions.
	The board may at any time provide that any stock options shall become immediately exercisable in full or in part, that any restricted stock awards shall be free of some or all restrictions, or that any other stock-based awards may become exercisable in full or in part or free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.
	The board or Compensation Committee may, in its sole discretion, amend, modify or terminate any award granted or made under the Stock Plan, so long as such amendment, modification or termination would not materially and adversely affect the participant.
	During the year ended December 31, 2014, options to purchase 703,000 shares of common stock at an exercise price of $0.028 per share were granted. The stock options will fully vest in April 2015. During the year ended December 31, 2013, options to purchase 100,000 shares of common stock at an exercise price of $0.042 per share were granted. The estimated fair value of stock options granted for the years ended December 31, 2014 and 2013, were $19,000 and $4,000, respectively.
	During the year ended December 31, 2014, stock options to purchase 100,000 shares of common stock at an exercise price of $0.042 per share became vested. During the year ended December 31, 2013, stock options to purchase 5,607,000 shares of common stock at an exercise price of $0.06 per share became vested. The estimated fair value of stock options which vested during the years ended December 31, 2014 and 2013 was $4,000 and $358,000, respectively.
	There were 703,000 unvested stock options with an exercise price of $0.028 per share, outstanding at December 31, 2014.
	During the years ended December 31, 2014 and 2013, the Company recorded non-cash stock-based compensation expense related to employee stock options amounting to $17,000 and $179,000, respectively.
	A summary of the activity in the Company’s Stock Option Plan is as follows:
			Exercise Price Per Share		Number Outstanding		Weighted Average Remaining Contractual Life	Number Exercisable		Weighted Average Exercise Price			Weighted Average Fair Value Per Stock Option at Date of Grant
	Balance, 1/1/13		$0.060 - $1.000		11,697,000		12	6,090,000		$	0.194		$	0.18
	Stock options granted		0.042		100,000		14	-			0.042			0.042
	Vested		0.06		-		13	5,607,000			0.06			0.064
	Balance, 12/31/13		0.042 – 1.000		11,797,000		12	11,697,000			0.193			0.179
	Stock options granted		0.028		703,000		15	-			0.028			0.028
	Vested		0.042		-		14	100,000			0.42			0.042
	Balance, 12/31/14		$0.028 – $1.000		12,500,000		12	11,707,000		$	0.184		$	0.169
	The weighted average fair value of the Company's stock options was estimated using the Black-Scholes option pricing model which requires highly subjective assumptions including the expected stock price volatility. These assumptions were as follows:
	●	Historical stock price volatility		139% - 325%
	●	Risk-free interest rate		0.21% - 4.64%
	●	Expected life (in years)		4
	●	Dividend yield		0
	The valuation assumptions were determined as follows:
	●	Historical stock price volatility: The Company utilized the volatility in the trading of its common stock computed for the 12 months of trading immediately preceding the date of grant for options granted in 2014 and 2013.
	●	Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of the grant for a period that is commensurate with the assumed expected option life.
	●	Expected life: The expected life of the options represents the period of time options are expected to be outstanding. The Company has very limited historical data on which to base this estimate. Accordingly, the Company estimated the expected life based on its assumption that the executives will be subject to frequent blackout periods during the time that the stock options will be exercisable and based on the Company’s expectation that it will complete its research and development phase and commence its initial production phase. The vesting period of these options was also considered in the determination of the expected life of each stock option grant.
	●	No expected dividends.
	The following table sets forth information with respect to stock options outstanding at December 31, 2014:
	Name		Title		Number of Shares of Common Stock Underlying Stock Options			Exercise Price per Share				Option  Expiration  Date
	George J. Coates		Chairman, Chief  Executive			1,000,000	-1	$	0.44			10/23/21
			Officer and President			50,000	-1		0.43			11/4/24
						275,000	-1		0.4			11/17/25
						1,800,000	-1		0.25			7/25/26
						1,815,000	-1		0.06			6/24/27
	Gregory G. Coates		Director and President,			500,000	-1		0.44			10/23/21
			Technology Division			1,800,000	-1		0.24			8/8/26
						351,000	-2		0.028			4/30/29
	Barry C. Kaye		Director, Treasurer and			125,000	-1		0.44			10/18/21
			Chief Financial Officer			100,000	-1		0.042			12/11/28
						351,000	-2		0.028			4/30/29
	Dr. Frank J. Adipietro		Non-employee Director			25,000	-1		0.44			3/28/22
						50,000	-1		0.43			11/3/24
						85,000	-1		0.4			11/17/25
						667,000	-1		0.06			6/24/27
	Dr. Richard W. Evans		Non-employee Director and Secretary			25,000	-1		0.44			3/28/22
						50,000	-1		0.39			12/27/24
						200,000	-1		0.25			2/15/26
						3,125,000	-1		0.06			6/20/27
	Dr. Michael J. Suchar		Non-employee Director			25,000	-1		0.44			3/28/22
	Richard Whitworth		Non-employee Director			25,000	-1		0.44			3/28/22
	William Wolf. Esq.		Outside General Counsel			25,000	-1		0.44			4/4/22
	Company Supplier		Company Supplier			30,000	-1		1			10/7/15
	(1) These stock options are fully vested.
	(2) These options will fully vest in April 2015.

Equity_Purchase_and_Registrati

Equity Purchase and Registration Rights Agreements	12 Months Ended
	Dec. 31, 2014
Equity Purchase and Registration Rights Agreements [Abstract]
EQUITY PURCHASE AND REGISTRATION RIGHTS AGREEMENTS	22. EQUITY PURCHASE AND REGISTRATION RIGHTS AGREEMENTS
	Southridge Partners II LP
	On July 2, 2014, the Company entered into a 3-year equity purchase agreement (the “EP Agreement”) with Southridge Partners II LP, a Delaware limited partnership (“Southridge”). Pursuant to the terms of the EP Agreement, Southridge committed to purchase up to 40,000,000 million shares of the Company’s common stock, in exchange for consideration not to exceed Ten Million ($10,000,000) Dollars. The purchase price for the shares of common stock shall be equal to 94% of the lowest daily Volume Weighted Average Price (“VWAP”) of the stock during the ten trading days that comprise the defined pricing period. The Company is entitled to exercise a Put to Southridge by delivering a Put Notice, which requires Southridge to remit the dollar amount stated in the Put Notice at the end of the pricing period, provided, however, that for each day during the pricing period, if any, that the daily VWAP of the Company’s common stock falls 25% or more below the Floor Price, as hereinafter defined, then the dollar amount of the Put shall be reduced by 10% for each such day. The Company may stipulate a Floor Price below which, no shares of common stock may be sold by Southridge, however, the Floor price shall not be lower than the lowest daily VWAP during the ten trading days preceding the date of the Put Notice.
	The Company also entered into a registration rights agreement (the “Registration Rights Agreement”) with Southridge. Pursuant to the terms of the Registration Rights Agreement, in August 2014, the Company filed a registration statement with the SEC covering 40,000,000 shares of common stock underlying the EP Agreement, which was declared effective on September 10, 2014.
	As of December 31, 2014, no Put Notices had been delivered to Southridge under the EP Agreement.
	Dutchess Opportunity Fund II, LP
	In 2011, the Company entered into an investment agreement (the “Investment Agreement”) with Dutchess Opportunity Fund II, LP, a Delaware limited partnership (“Dutchess”). Pursuant to the terms of the Investment Agreement, Dutchess committed to purchase, in a series of purchase transactions (“Puts”) registered shares of the Company’s common stock. The Investment Agreement automatically terminated on August 12, 2014.
	The purchase price paid by Dutchess for the registered shares of common stock delivered with each Put was equal to ninety-four percent (94%) of the lowest daily VWAP of the common stock during the five-day trading period beginning on the effective date of the Put.
	During the years ended December 31, 2014 and 2013, the Company sold 4,403,403 and 3,618,676 registered shares of its common stock, respectively, under this equity line of credit with Dutchess and received proceeds of $162,000 and $156,000, respectively, which were used for general working capital purposes. There were no offering costs related to the sales of these shares.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
INCOME TAXES	23. INCOME TAXES
	Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.
	Deferred tax assets increased by $3,178,000 and $834,000 for the years ended December 31, 2014 and 2013, respectively. These amounts were fully offset by a corresponding increase in the tax valuation allowance resulting in no net change in deferred tax assets, respectively, during these periods.
	No liability for unrecognized tax benefits was required to be reported at December 31, 2014 and 2013.  Based on the Company's evaluation, it has concluded that there are no significant uncertain tax positions requiring recognition in the Company's financial statements.  The Company's evaluation was performed for tax years ended 2010 through 2013, the only periods subject to examination.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate that adjustments, if any, will result in a material change to its financial position. For the years ended December 31, 2014 and 2013, there were no penalties or interest related to the Company’s income tax returns.
	Total deferred tax assets and valuation allowances are as follows at December 31:
		2014			2013
	Current deferred tax asset - inventory reserve	$	195,000		$	195,000
	Non-Current Deferred Tax Assets:
	Net operating loss carryforwards		6,475,000			6,201,000
	Stock-based compensation expense		4,242,000			1,688,000
	Accrued liabilities not paid		464,000			481,000
	Deferred compensation not paid within 2.5 months		432,000			115,000
	Accrued interest on notes to related parties		159,000			115,000
	Total long-term deferred tax assets		11,772,000			8,600,000
	Total deferred tax assets		11,967,000			8,795,000
	Less: valuation allowance		(11,967,000	)		(8,795,000	)
	Net deferred tax assets	$	-		$	-
	The differences between income tax (benefit) provision in the financial statements and the income tax (benefit) provision computed at the U.S. Federal statutory rate of 34% at December 31 are as follows:
		2014			2013
	Federal tax provision at the statutory rate		34	%		34	%
	State income tax provision (benefit), net of federal benefit		(2.2	)		(2.7	)
	Stock-based compensation expense		(20.0	)		(9.1	)
	Deferred compensation not paid within 2.5 months		(2.5	)		(4.2	)
	Accrued interest not deductible for tax return purposes		(2.5	)		(6.0	)
	Net change in net operating loss carryforwards		(2.1	)		(15.5	)
	Increase in estimated fair value of embedded derivative liabilities		(0.3	)		(3.1	)
	Accrued liabilities not deductible for tax return purposes		0.3			0.4
	Officer’s life insurance		(0.0	)		(0.2	)
	Total		(4.7	)		(6.4	)
	Valuation allowance		4.7			6.4
	Effective tax rate		0	%		0	%
	At December 31, 2014, the Company had available, $17,305,000 of net operating loss carryforwards which may be used to reduce future federal taxable income, expiring between 2018 and 2034. At December 31, 2014, the Company had available $7,456,000 of net operating loss carryforwards which may be used to reduce future state taxable income, expiring between 2015 and 2034.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
	24. RELATED PARTY TRANSACTIONS
	Issuances of Common Stock and Warrants
	Issuances of common stock and common stock warrants to related parties during the years ended December 31, 2014 and 2013 are discussed in detail in Note 16.
	Promissory notes to related parties converted into restricted shares of the Company’s common stock are discussed in detail in Note 13.
	Issuances of Promissory Notes to Related Parties
	Issuances of promissory notes to related parties during the years ended December 31, 2013 and 2012 to related parties are discussed in detail in Note 13.
	The promissory notes to related parties are payable on demand and provide for interest at the rate of 17% per annum, compounded monthly.
	At December 31, 2014, interest accrued but not paid on outstanding promissory notes to related parties, aggregated $342,000.
	Stock Options Granted
	Stock options granted to related parties during the years ended December 31, 2014 and 2013 are discussed in detail in Note 21.
	Issuances of Preferred Stock
	Shares of Series A Preferred Stock awarded to George J. Coates during the years ended December 31, 2014 and 2013 is discussed in detail in Note 16.
	Shares of Series B Convertible Preferred Stock awarded to George J. Coates, Gregory G. Coates and Barry C. Kaye during the year ended December 31, 2014 is discussed in detail in Note 16.
	Personal Guaranty and Stock Pledge
	In connection with the Company’s mortgage loan, George J. Coates has pledged certain of his shares of common stock of the Company to the extent required by the lender and provided a personal guaranty as additional collateral for a mortgage loan on the Company’s headquarters facility.
	In connection with the Company’s sale/leaseback of its research and development and manufacturing equipment, George J. Coates provided his personal guaranty.
	Compensation and Benefits Paid
	The approximate amount of compensation and benefits, all of which were approved by the board, paid to George J. Coates, Gregory G. Coates and Bernadette Coates, exclusive of stock-based compensation for unregistered, restricted shares of Preferred Stock awarded to George J. Coates and Gregory G. Coates and non-cash, stock-based compensation for employee stock options granted to Gregory G. Coates is summarized as follows:
				For the Year Ended,
				2014		2013
		George J. Coates (a) (b) (c) (d) (e) (f) (g)		$	16,000	$	29,000
		Gregory G. Coates (h) (i)			177,000		169,000
		Bernadette Coates (j)			4,000		15,000
		(a)	For the years ended December 31, 2014 and 2013, George J. Coates earned additional base compensation of $250,000 and $231,000, respectively, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheets at December 31, 2014 and 2013.
		(b)	During the year ended December 31, 2014, George J. Coates received a compensatory award of $950,000 in the form of a non-interest bearing promissory note to compensate him for the lost benefits of ownership of the property he contributed to the Company as more fully discussed in Note 13.
		(c)	During the period from January 1, 2014 to July 2, 2014 and the year ended December 31, 2013, 40,191 and 68,590 shares of Series A Preferred Stock, respectively, having an estimated fair value of $100,000 and $170,000, respectively, were granted and issued to George J. Coates pursuant to an anti-dilution agreement. On July 3, 2014 181,664 shares of Series A Preferred Stock comprising all of the shares of Series A Preferred Stock previously issued to George J. Coates were converted into 181,664 shares of Series B Convertible Preferred Stock, $0.001 par value per share.
		(d)	On August 1, 2014, 50,000 shares of Series A Preferred Stock with an estimated fair value of $69,000, were issued to George J. Coates as an inducement to him to consider future offers from investors to acquire substantial ownership interests in the Company as a means of raising substantial new working capital for the Company.
		(e)	During the year ended December 31, 2014, George J. Coates was awarded 541,933 shares of Series B Convertible Preferred Stock with an estimated fair value of $8,070,000 for anti-dilution. Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
		(f)	During the year ended December 31, 2013, George J. Coates was awarded 14,142,085 unregistered shares of the Company’s common stock for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares, based on the closing trading price of the stock on the dates of issuance was $430,000 which was charged to stock-based compensation expense for the the year ended December 31, 2013. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, unissued status.
		(g)	In January 2013, the Company issued 20,895,046 unregistered shares of its common stock to George J. Coates in satisfaction of a deferred compensation liability consisting of 20,275,046 shares for anti-dilution protection for the year ended December 31, 2012 and a 620,000 share stock award originally granted in 2011. The value of these shares, based on the closing trading price on the dates of the anti-dilution or the date of the stock award was $1,761,000, of which $1,674,000 and $87,000 was charged to stock-based compensation expense during the years ended December 31, 2012 and 2011, respectively. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, unissued status.
		(h)	Includes compensation paid in 2014 for vacation earned but not taken.
		(i)	During the year ended December 31, 2014, Gregory G. Coates was awarded 40,593 shares of Series B Convertible Preferred Stock with an estimated fair value of $607,000 for anti-dilution. Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
		(j)	For the years ended December 31, 2014 and 2013, Bernadette Coates earned additional base compensation of $67,000 and $57,000, respectively, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheets at December 31, 2014 and 2013.
	During the years ended December 31, 2014 and 2013, Barry C. Kaye, Treasurer and Chief Financial Officer was paid compensation of $170,000 and $40,000, respectively. For the year ended December 31, 2014, Mr. Kaye earned compensation of $78,000 which was not paid and is being deferred until the Company has sufficient working capital to remit payment to him. This amount is included in accounts payable and accrued liabilities in the accompanying balance sheet at December 31, 2014. During the year ended December 31, 2014, Barry C. Kaye was awarded 2,976 shares of Series B Convertible Preferred Stock with an estimated fair value of $44,000 for anti-dilution. Each share of Series B Convertible Preferred Stock becomes convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.

Contractual_Obligations_and_Co

Contractual Obligations and Commitments	12 Months Ended
	Dec. 31, 2014
Contractual Obligations and Commitments / Litigation and Contingencies [Abstract]
CONTRACTUAL OBLIGATIONS AND COMMITMENTS	25. CONTRACTUAL OBLIGATIONS AND COMMITMENTS
	The following table summarizes our contractual obligations and commitments at December 31, 2014:
				Due Within
		Total		2015		2016
	Promissory notes to related parties	$	1,566,000	$	1,566,000	$	-
	Mortgage loan payable		1,448,000		1,448,000		-
	Deferred compensation		1,080,000		1,080,000		-
	Convertible promissory notes		696,000		576,000		120,000
	Finance lease obligation		94,000		72,000		22,000
	Settlement of litigation		10,000		10,000		-
	Total	$	4,894,000	$	4,752,000	$	142,000
	Total non-cash compensation cost related to nonvested stock options at December 31, 2014 that has not been recognized was $7,000. This compensation expense will be recognized in the future over a remaining weighted average period of approximately 4 months.

Litigation_and_Contingencies

Litigation and Contingencies	12 Months Ended
	Dec. 31, 2014
Contractual Obligations and Commitments / Litigation and Contingencies [Abstract]
LITIGATION AND CONTINGENCIES	26. LITIGATION AND CONTINGENCIES
	The Company is not a party to any other litigation that is material to its business.

Recently_Issued_Accounting_Sta

Recently Issued Accounting Standards	12 Months Ended
	Dec. 31, 2014
Recently Issued Accounting Standards [Abstract]
RECENTLY ISSUED ACCOUNTING STANDARDS	27. RECENTLY ISSUED ACCOUNTING STANDARDS
	In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40)”, which was issued in order to provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related financial statement disclosures. It requires that management evaluate whether there are conditions or events, when considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date of both the annual and interim financial statements (“Going Concern Doubt”). The evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date of the financial statements. When such evaluation determines that Going Concern Doubt does exist, then management is required to consider whether or not it is probable that its plans to mitigate the Going Concern Doubt can be effective and timely to address the Going Concern Doubt. This update further provides disclosure requirements in the notes to financial statements both when such doubt is probable of being mitigated and when such doubt is not probable of being mitigated by management’s plans. This update is to become effective for annual and interim financial statements for fiscal years ending after December 15, 2016. As permitted thereunder, the Company has elected to implement this update early and it has been applied in the financial statements for the year ended December 31, 2014. Early adoption did not have a material effect on the Company’s financial position or results of operations.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers,” (Topic 606): which amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company will be required to adopt this accounting standard in the first quarter of fiscal 2018. Early adoption is not permitted. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is currently evaluating the impact of these amendments and the transition alternatives, however, at this time it does not anticipate that it will have a material effect on its financial statements.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This update requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless the net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under applicable tax law or if the company does not intend to use the tax benefit towards the settlement of a disallowed tax position, if any. Adoption of this standard did not have a material effect on the Company’s financial statements.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	28. SUBSEQUENT EVENTS
	Grant of Non-Exclusive Distribution Sublicense
	In February 2015, the Company granted a non-exclusive distribution sublicense to Renown Power Development, Ltd., a China-based sales and distribution company (“Renown”) covering the territory defined as the Western Hemisphere. Under this sublicense, Renown will be permitted to sell, lease and distribute CSRV® products. This sublicense provides for payment of licensing fees amounting to US$100 million. The Company received an initial non-refundable deposit of $500,000 to date. In addition, after Renown receives an aggregate of US$10,000,000, it is required to pay the Company 25% of all funds it receives from any and all sources until the entire US$100 million licensing fee is paid in full. In the event that Renown completes one or more capital raises aggregating US$300 million or more, the then remaining unpaid balance of the US$100 million licensing fee shall become immediately due and payable.
	As collateral for payment of the sublicensing fee, Coates Power, Ltd. an independent China-based manufacturing company that will produce CSRV® products in China (“Coates Power”) and Renown are to place shares of their capital stock representing a 25% ownership interest into an escrow account for the benefit of the Company. These shares of stock will be released from escrow and revert back to Coates Power and Renown only after the US$100 million sublicensing fee is paid in full. The Company does not have an ownership interest in Coates Power or Renown. Coates Power and Renown are controlled and managed by Mr. James Pang, the Company’s liaison agent in China.
	Coates Power has agreed to initially source it production parts and components from the Company. To date, the Company has sold Coates Power approximately US$131,000 in production parts and components in connection with their plan to manufacture two Gen Sets.
	Issuance of Convertible Promissory Note
	In March 2015, the Company issued a $52,500 convertible promissory note which bears interest at the rate of 9.75% per annum. The Company received net proceeds of $50,000 after transaction costs. The holder may convert the convertible note at any time beginning six months after funding, into shares of the Company's common stock at a fixed rate of $0.055 per share. In addition, there are mandatory monthly conversions beginning 180 days after funding. Each monthly conversion amount shall generally be equal to one-twelfth of the original amount of the note, plus accrued interest. The Company may, at its option, pay any installment in whole, or in part, in cash. Any portion of a monthly installment not paid in cash is convertible into shares of the Company's common stock. The number of shares of common stock to be initially delivered upon conversion shall be equal to the dollar amount being converted divided by the variable conversion price. The variable conversion price is the lesser of $0.055 per share, or 70% of the average of the three lowest daily volume weighted average prices (“VWAP”) over the 15 trading day period prior to the date of conversion. The number of shares of the Company's common stock required to be issued to the investor upon any mandatory conversion may be subsequently adjusted upward in the event that the recalculated variable conversion price on the 23rd trading day following the date the conversion shares are received by the holder is lower than the calculated variable conversion price on the date of conversion. In such case, the Company would be required to deliver the incremental number of shares to the investor, determined based on the recalculated variable conversion price.
	Conversion and Repayment of Convertible Promissory Notes
	In a series of transactions from January through March 2015, $409,000 principal amount of convertible promissory notes and $24,000 of accrued interest thereon, were converted into 134,424,332 unregistered shares of the Company’s common stock. In February 2015, $27,000 principal amount of a convertible promissory note, including accrued interest thereon, was repaid without penalty. As a result of the conversions, repayment and issuance of the $52,500 convertible note, the principal amount of convertible promissory notes was reduced to $339,000 from the balance of $696,000 at December 31, 2014.
	Issuance of Anti-dilution shares
	In a series of transactions from January through March 2015, the Company issued 640,657, 43,614 and 3,414 shares of Series B Convertible Preferred Stock to George J. Coates, Gregory G. Coates and Barry C. Kaye, respectively, representing anti-dilution shares related to newly issued shares of common stock. The estimated fair value of these shares was $2,034,000, $138,000 and $11,000, respectively.
	Issuances and Repayments of 17% Promissory Notes to Related Parties
	In March 2015, the Company issued $40,000 of 17% promissory notes due to George J. Coates Company and partially repaid 17% promissory notes due to George J. Coates and Bernadette Coates amounting $58,000 and $9,000, respectively.
	Deferred Compensation
	As of March 30, 2015, George J. Coates, Barry C. Kaye and Bernadette Coates agreed to additional deferral of their compensation amounting to $63,000, $13,000 and $17,000, respectively, bringing their total deferred compensation to $543,000, $92,000 and $141,000, respectively.
	Designation of Additional Shares of Series B Convertible Preferred Stock
	In March 2015, the board of directors designated an additional four million shares of Series B Preferred Stock, par value $0.001 per share bringing the total number of designated shares to five million.

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
The Company and Summary of Significant Accounting Policies [Abstract]
Nature of Organization	Nature of Organization
	Coates International, Ltd. is a Delaware corporation organized in October 1991 as successor-in-interest to a Delaware corporation of the same name incorporated in August 1988.  Coates International, Ltd. operates in Wall Township, New Jersey.
	The Company has acquired the exclusive licensing rights for the Coates spherical rotary valve (“CSRV®”) system technology in North America, Central America and South America (the “CSRV® License”). The CSRV® system technology has been developed over a period of more than 20 years by the Company’s founder George J. Coates and his son Gregory G. Coates. The CSRV® system technology is adaptable for use in piston-driven internal combustion engines of many types and has been patented in the United States and numerous countries throughout the world.
	The CSRV® system technology is designed to replace the intake and exhaust conventional “poppet valves” currently used in almost all piston-driven, automotive, truck, motorcycle, marine and electric power generator engines, among others. Unlike conventional valves which protrude into the engine cylinder, the CSRV® system technology utilizes spherical valves that rotate in a cavity formed between a two-piece cylinder head. The CSRV® system technology utilizes significantly fewer moving parts than conventional poppet valve assemblies. As a result of these design improvements, management believes that engines incorporating the CSRV® system technology (“Coates Engines”) will last significantly longer and will require less lubrication over the life of the engine, as compared to conventional engines. In addition, CSRV®Engines can be designed with larger openings into the engine cylinder than with conventional valves so that more fuel and air can be inducted into, and expelled from, the cylinder in a shorter period of time. Larger valve openings permit higher revolutions-per-minute (RPM’s) and permit higher compression ratios with lower combustion chamber temperatures, allowing the Coates Engine to produce more power than equivalent conventional engines. The extent, to which higher RPM’s, greater volumetric efficiency and thermal efficiency can be achieved with the CSRV® system technology, is a function of the engine design and application.
Hydrogen Reactor Technology Owned by George J. Coates	Hydrogen Reactor Technology Owned by George J. Coates
	George J. Coates has developed a hydrogen reactor, which rearranges H2O water molecules into HOH molecules also known as Hydroxy-Gas. The Hydroxy-Gas produced by the hydrogen reactor is then harvested for use as a type of fuel. Mr. Coates intends to continue with development of this technology to enable the harvested Hydroxy-Gas to be utilized as the fuel source to power our patented CSRV® engines. The next phase of this research and development will focus on powering larger, industrial engines. If successful, this application will only require a ready supply of water and would be suitable for stationary engines and generators. Conventional internal combustion engines employing poppet valve assemblies require lubrication and would experience excessive heat and friction if powered with Hydroxy-Gas. This, in turn, would cause the engines to burn out in a rather short period of time. The materials and components of the CSRV® engines do not require such lubrication and because of their design, are able to operate relatively trouble-free on Hydroxy-Gas as the engine fuel. There can be no assurance that this technology can be developed successfully, or that if developed, it will be feasible to penetrate the internal combustion engine market with this technology. Applications for patent protection of this technology will be filed upon completion of the research and development. Although at this time no arrangements have been made between the Company and George J. Coates, owner of the technology, regarding licensing of the hydrogen reactor, Mr. Coates has provided his commitment to license this technology to the Company once the related patent protection is in place. Accordingly, the Company does not currently have any rights to manufacture, use, sell and distribute the Hydrogen Reactor technology, should it become commercially feasible to manufacture and distribute products powered by the Hydroxy-Gas fuel. The Company has been and continues to be responsible for all costs incurred related to the development of this technology.
Basis of Presentation	Basis of Presentation
	The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and rules and regulations of the Securities and Exchange Commission (the “SEC”).
	Since the Company’s inception, the Company has been responsible for the development costs of the CSRV® technology in order to optimize the value of the licensing rights and has incurred related operational costs, the bulk of which have been funded primarily through cash generated from licensing fees, sales of stock, short term convertible promissory notes, capital contributions, loans made by George J. Coates, Bernadette Coates, his spouse and certain directors, fees received from research and development of prototype models and a small number of CSRV® engine generator sales. The Company has incurred substantial cumulative losses from operations since its inception. Losses from operations are expected to continue until the Coates Engines are successfully introduced into and accepted in the marketplace, or the Company receives substantial licensing revenues. These losses from operations were substantially related to research and development of the Company’s intellectual property rights, patent filing and maintenance costs and general and administrative expenses. The Company has also incurred substantial non-cash expenses for stock-based compensation.
	As shown in the accompanying financial statements, the Company has incurred recurring losses from operations and, as of December 31, 2014, had a stockholders’ deficiency of ($5,434,000). The Company will be required to renegotiate the terms of an extension of a $1,448,000 mortgage loan which matures in July 2015 or successfully refinance the property with another mortgage lender, if possible. Failure to do so could adversely affect the Company’s financial position and results of operations. In addition, the current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest their funds and low investor confidence, has introduced additional risk and difficulty to the Company’s challenge to secure needed additional working capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management has instituted a cost control program intended to restrict variable costs to only those expenses that are necessary to complete its activities related to entering the production phase of operations, develop additional commercially feasible applications of the CSRV® system technology, seek additional sources of working capital and cover general and administrative costs in support of such activities. The Company has been actively undertaking efforts to secure new sources of working capital. At the December 31, 2014, the Company had negative working capital of ($7,296,000) compared with negative working capital of ($5,078,000) at the end of 2013.
	During the years ended December 31, 2014 and 2013, the Company raised $2,181,000 and $917,000, respectively, of new working capital from the following:
		Description		2014		2013
		Issuance of convertible promissory notes		$	996,000	$	398,000
		Sales of shares of common stock and warrants to the son of a director			515,000		125,000
		Deposit on non-exclusive distribution license with China-based company			498,000		-
		Sales of common stock under equity line of credit			162,000		156,000
		Proceeds from exercise of common stock warrants			10,000		10,000
		Proceeds from sale/leaseback of equipment			-		133,000
		Issuances of promissory notes to related parties, net of repayments			-		95,000
				$	2,181,000	$	917,000
	In the fourth quarter of 2011, the Company identified cracks on the lower engine heads of its Gen Sets that resulted from a defect in the manufacturing by one of its suppliers. Based on testing of the Gen Set to confirm the Company’s resolution of this problem, management believes it has determined the cause of this cracked head condition. The Company has placed orders for new production parts, including sets of engine heads and has also modified certain patterns with the goal of manufacturing a limited number of Gen Sets. Thereafter, it will undertake field testing of the Gen Sets, after which, it will begin to ramp-up production.
	The Company continues to actively seek out new sources of working capital; however, there can be no assurance that it will be successful in these efforts. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Certain amounts included in the accompanying financials statements for the year ended December 31, 2013 have been reclassified in order to make them comparable to the amounts presented for the year ended December 31, 2014.
Majority-Owned Subsidiary	Majority-Owned Subsidiary
	CIL is currently the majority shareholder of Coates Hi-Tech Engines, Ltd., a Delaware corporation which was formed in July 2012. It has not commenced operations and has no assets.
Revenue Recognition	Revenue Recognition
	Sales and cost of sales are recognized at the time of shipment, provided the risk of loss has transferred to the customer and collection of the sales price is reasonably assured. Shipping arrangements and costs are the responsibility of the customer.
	Revenue from research and development activities is recognized when collection of the related revenues is reasonably assured and, when applicable, in accordance with Accounting Standards Update No. 2010-17, “Milestone Method of Revenue Recognition, a consensus of the FASB Emerging Issues Task Force”. This standard provides guidance on defining a milestone and permits recognition of revenue from research and development that is contingent upon achievement of one or more specified milestones defined in the research and development arrangements which meet specified criteria for such revenue recognition.
	Unearned revenue represents a deposit from a customer for a CSRV® Gen Set order. Revenue is recognized as described above.
	License deposits, which are non-refundable, were received from the granting of sublicenses and are recognized as earned, generally commencing upon the completion of certain tests of the CSRV® products and acceptance by the licensee. At that time, license revenue will be recognized ratably over the period of time that the sublicense has been granted using the straight-line method. Upon termination of a sublicense agreement, non-refundable license deposits, less any costs related to the termination of the sublicense agreement, are recognized as revenue. Revenue from research and development activities is recognized when earned and realization is reasonably assured, provided that financial risk has been transferred from the Company to its customer.
	The Company is recognizing the license deposit of $300,000 on the Canadian License as revenue on a straight-line basis over the approximate remaining life through 2027 of the last CSRV® technology patent in force.
Research and Development	Research and Development
	Research and development costs are expensed when incurred. Included in accounts payable and accrued liabilities at December 31, 2014 and 2013 is $115,000 for the estimated remediation costs of previously sold Gen Sets that were determined to have cracked heads.
Intellectual Property	Intellectual Property
	Under a licensing agreement with George J. Coates and Gregory G. Coates, the Company obtained the rights to manufacture, use and sell the CSRV® engine technology throughout the territory defined as the Western Hemisphere. In accordance with GAAP, the Company is not permitted to record a value for this intellectual property because it was obtained from principal stockholders, and, accordingly this intangible asset is not reflected in the accompanying financial statements.
Licensing Costs	Licensing Costs
	Under the CSRV® Licensing Agreement for the CSRV® engine technology, the Company is responsible for all costs in connection with applying for and maintaining patents to protect the CSRV® system technology. Such costs are expensed as incurred.
Advertising and Marketing Costs	Advertising and Marketing Costs
	Advertising costs, which are included in marketing expenses, are expensed when incurred. Advertising expense amounted to $48,000 and $3,000 for the years ended December 31, 2014 and 2013, respectively. In the year ended December 31, 2014, advertising and marketing costs included $45,000 in fees to agents in China and the Middle East for their assistance in introducing our CSRV technology and presenting proposals to potential investors interested in entering into a sublicense arrangement with the Company.
Stock-Based Compensation	Stock-Based Compensation
	Stock-based compensation expense, which does not require any outlay of cash, consists of the following:
		●	The estimated fair value of shares of the Company’s capital stock issued to key employees for anti-dilution protection pursuant to a resolution of the board of directors. This includes restricted shares of Series A Preferred Stock and Series B Convertible Stock. In 2014, the Company arranged for an independent professional services firm to determine the estimated fair value of Series A Preferred Stock issued in August 2014 and Series B Preferred Stock issued in July 2014. The approach to arriving at the estimated fair value of the Series B Convertible Preferred Stock was determined to have a close correlation to the trading price of the Company’s common stock. Accordingly, upon each subsequent issuance of shares of Series B Convertible Preferred Stock, the original estimated fair value determined by the independent valuation is adjusted, on a pro rata basis, to reflect the closing price of the Company’s common stock on each date of issuance.
		●	Compensation expense relating to stock options and stock awards under its stock option and incentive plans is recognized as an expense using the fair value measurement method. Under the fair value method, the estimated fair value of awards to employees is charged to income on a straight-line basis over the requisite service period, which is the earlier of the employee’s retirement eligibility date or the vesting period of the award.
Deferred Compensation	Deferred Compensation
	Deferred compensation represents salaries of George J. Coates and Bernadette Coates earned but not paid in order to preserve the Company’s working capital. The Company intends to repay these amounts at such time that it has sufficient working capital and after the related party notes to George J. Coates and Bernadette Coates have been repaid with interest thereon. Also included in deferred compensation is the estimated amount of personal income taxes of George J. Coates that the Company is obligated to pay in connection with certain shares of stock that he received to compensate him for lost benefits of ownership of the Company’s headquarters, research and development and warehouse facility subsequent to the date he contributed this property to the Company, without having received any compensation therefor.
Inventory	Inventory
	Inventory consists of raw materials and work-in-process, including overhead and is stated at the lower of cost or market determined by the first-in, first-out method. Inventory items designated as obsolete or slow moving are reduced to net realizable value. Market value is determined using current replacement cost.
Property, Plant and Equipment	Property, Plant and Equipment
	Property, plant and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful life of the assets: 40 years for buildings and building improvements, 3 to 7 years for machinery and equipment and 5 to 10 years for furniture and fixtures. Repairs and maintenance expenditures, which do not extend the useful lives of the related assets, are expensed as incurred.
	In the event that facts and circumstances indicate that long-lived assets may be impaired, an evaluation of recoverability is performed. Should such evaluation indicate that there has been an impairment of one or more long-lived assets, the cost basis of such assets would be adjusted accordingly at that time.
Income Taxes	Income Taxes
	Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized and are adjusted when conditions indicate that deferred assets will be realized. Income tax expense (benefit) is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.
	The Company evaluates any uncertain tax positions for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes. In the event recognition of an uncertain tax position is indicated, the Company measures the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. This process of evaluating and estimating uncertain tax positions and tax benefits requires the consideration of many factors, which may require periodic adjustments and which may not accurately forecast actual outcomes. Interest and penalties, if any, related to tax contingencies would be included in income tax expense.
Loss per Share	Loss per Share
	Basic net loss per share is based on the weighted average number of common shares outstanding without consideration of potentially dilutive shares of common stock. There were no shares of preferred stock outstanding with rights to share in the Company’s net income during the years ended December 31, 2014 and 2013. Diluted net income per share is based on the weighted average number of common and potentially dilutive common shares outstanding, when applicable.
Use of Estimates	Use of Estimates
	The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives and variable conversion rates, determining a value for shares of Series A Preferred Stock and Series B Convertible Stock issued and certain limited anti-dilution rights granted to George J. Coates as more fully described in Note 16, assigning useful lives to the Company’s property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, estimating a valuation allowance for deferred tax assets, assigning expected lives to, and estimating the rate of forfeitures of, stock options granted and selecting a trading price volatility factor for the Company’s common stock in order to estimate the fair value of the Company’s stock options on the date of grant or other appropriate measurement date. Actual results could differ from those estimates.

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
The Company and Summary of Significant Accounting Policies [Abstract]
Summary of new working capital
		Description	2014		2013
		Issuance of convertible promissory notes	$	996,000	$	398,000
		Sales of shares of common stock and warrants to the son of a director		515,000		125,000
		Deposit on non-exclusive distribution license with China-based company		498,000		-
		Sales of common stock under equity line of credit		162,000		156,000
		Proceeds from exercise of common stock warrants		10,000		10,000
		Proceeds from sale/leaseback of equipment		-		133,000
		Issuances of promissory notes to related parties, net of repayments		-		95,000
			$	2,181,000	$	917,000

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory [Abstract]
Summary of inventory
		2014			2013
	Raw materials	$	381,000		$	440,000
	Work-in-process		53,000			59,000
	Finished goods		-			-
	Less: Reserve for obsolescence		(387,000	)		(387,000	)
	Total	$	47,000		$	112,000

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Summary of Property, plant and equipment		2014			2013
	Land	$	1,235,000		$	1,235,000
	Building		964,000			964,000
	Building improvements		83,000			83,000
	Machinery and equipment		658,000			658,000
	Furniture and fixtures		39,000			39,000
			2,979,000			2,979,000
	Less:  Accumulated depreciation		(860,000	)		(799,000	)
	Total	$	2,119,000		$	2,180,000

Accounts_Payable_and_Accrued_L1

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Summary of accounts payable and accrued liabilities
		2014		2013
	Legal and professional fees	$	1,290,000	$	1,388,000
	Accrued interest expense		374,000		264,000
	General and administrative expenses		194,000		301,000
	Research and development costs		115,000		115,000
	Accrued compensation and benefits		10,000		196,000
	Total	$	1,983,000	$	2,264,000

Convertible_Promissory_Notes_a1

Convertible Promissory Notes and Embedded Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2014
Convertible Promissory Notes and Embedded Derivative Liability [Abstract]
Convertible promissory notes and embedded derivative liabilities
			Principal Amount													Unamortized Discount				Embedded
																				Derivative Liability
	Date Issued		December 31, 2014		December 31, 2013		Nominal Interest Rate			Effective Interest Rate(1)			Conversion Price Discount from Defined Trading Price			December 31, 2014		December 31, 2013		December 31, 2014		December 31, 2013
	12/16/14		$	28,000		N/A		12	%		55	%		40	%	$	8,000		N/A	$	31,000		N/A
	12/5/14			53,000		N/A		8	%		160	%		39	%		42,000		N/A		20,000		N/A
	11/25/14			52,000		N/A		9.75	%		91	%		30	%		24,000		N/A		41,000		N/A
	11/14/14			40,000		N/A		8	%		139	%		32.5	%		30,000		N/A		54,000		N/A
	10/2/14			40,000		N/A		8	%		113	%		35	%		16,000		N/A		43,000		N/A
	9/29/14			53,000		N/A		8	%		118	%		39	%		29,000		N/A		20,000		N/A
	9/3/14			39,000		N/A		12	%		139	%		40	%		15,000		N/A		38,000		N/A
	8/29/14			53,000		N/A		8	%		105	%		39	%		13,000		N/A		17,000		N/A
	8/8/14			52,000		N/A		9.75	%		72	%		30	%		5,000		N/A		41,000		N/A
	7/28/14			30,000		N/A		12	%		156	%		30	%		6,000		N/A		25,000		N/A
	7/9/14			83,000		N/A		8	%		120	%		39	%		5,000		N/A		15,000		N/A
	7/8/14			50,000		N/A		5	%		106	%		37	%		2,000		N/A		31,000		N/A
	6/12/14			47,000		N/A		8	%		147	%		40	%		-		N/A		46,000		N/A
	4/16/14			25,000		N/A		12	%		147	%		30	%		-		N/A		17,000		N/A
	4/16/14			24,000		N/A		12	%		175	%		40	%		-		N/A		15,000		N/A
	4/2/14			27,000		N/A		9.75	%		71	%		30	%		-		N/A		22,000		N/A
	12/11/13			-		28,000		10	%		134	%		42	%		N/A		22,000		N/A		43,000
	12/10/13			-		28,000		12	%		117	%		40	%		N/A		19,000		N/A		45,000
	12/9/13			-		28,000		10	%		134	%		42	%		N/A		22,000		N/A		43,000
	11/27/13			-		32,000		8	%		133	%		39	%		N/A		25,000		N/A		33,000
	10/11/13			-		47,000		8	%		147	%		39	%		N/A		31,000		N/A		48,000
	8/14/13			-		28,000		12	%		147	%		40	%		N/A		14,000		N/A		45,000
	8/8/13			-		53,000		8	%		147	%		39	%		N/A		14,000		N/A		53,000
	6/4/13			-		28,000		12	%		92	%		40	%		N/A		-		N/A		45,000
	3/21/13			-		-		12	%		76	%		40	%		N/A		-		N/A		12,000
			$	696,000	$	272,000										$	195,000	$	147,000	$	476,000	$	367,000
		-1	The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.

Income_Loss_Per_Share_Tables

Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Income (Loss) Per Share [Abstract]
Schedule of potentially issuable shares of common stock	Description	Number of Underlying Shares of Common Stock		Exercise Price			Number Vested		Number Non-Vested
	Common stock options		703,000	$	0.028			-		703,000
	Common stock options		100,000		0.042			100,000		-
	Common stock options		5,607,000		0.06			5,607,000		-
	Common stock options		1,800,000		0.24			1,800,000		-
	Common stock options		2,000,000		0.25			2,000,000		-
	Common stock options		50,000		0.39			50,000		-
	Common stock options		360,000		0.4			360,000		-
	Common stock options		100,000		0.43			100,000		-
	Common stock options		1,750,000		0.44			1,750,000		-
	Common stock options		30,000		1			30,000		-
	Common stock warrants		1,750,000		0.02			N/A		N/A
	Common stock warrants		666,667		0.0225			N/A		N/A
	Common stock warrants		2,127,660		0.0235			N/A		N/A
	Common stock warrants		5,000,000		0.025			N/A		N/A
	Common stock warrants		1,739,130		0.02875			N/A		N/A
	Common stock warrants		333,333		0.03			N/A		N/A
	Common stock warrants		2,714,287		0.035			N/A		N/A
	Common stock warrants		7,125,000		0.04			N/A		N/A
	Common stock warrants		333,333		0.045			N/A		N/A
	Common stock warrants		400,000		0.05			N/A		N/A
	Common stock warrants		2,181,819		0.055			N/A		N/A
	Common stock warrants		171,428		0.057			N/A		N/A
	Common stock warrants		285,714		0.0581			N/A		N/A
	Common stock warrants		428,571		0.0585			N/A		N/A
	Common stock warrants		2,000,000		0.06			N/A		N/A
	Common stock warrants		4,269,838		0.0625			N/A		N/A
	Common stock warrants		333,333		0.0675			N/A		N/A
	Common stock warrants		571,429		0.07			N/A		N/A
	Common stock warrants		666,666		0.09			N/A		N/A
	Common stock warrants		416,667		0.12			N/A		N/A
	Common stock warrants		1,200,000		0.25			N/A		N/A
	Common stock warrants		833,333		0.27			N/A		N/A
	Common stock warrants		153,846		0.325			N/A		N/A
	Common stock warrants		142,857		0.35			N/A		N/A
	Convertible promissory notes		128,574,391		(1	)		N/A		N/A
	Total		176,919,302
	-1	The principal amount of convertible promissory notes outstanding at December 31, 2014, was $696,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2014.
	Description	Number of Underlying Shares of Common Stock		Exercise			Number Vested		Number Non-Vested
				Price
	Common stock options		100,000	$	0.042			-		100,000
	Common stock options		5,607,000		0.06			5,607,000		-
	Common stock options		1,800,000		0.24			1,800,000		-
	Common stock options		2,000,000		0.25			2,000,000		-
	Common stock options		50,000		0.39			50,000		-
	Common stock options		360,000		0.4			360,000		-
	Common stock options		100,000		0.43			100,000		-
	Common stock options		1,750,000		0.44			1,750,000		-
	Common stock options		30,000		1			30,000		-
	Common stock warrants		500,000		0.02			N/A		N/A
	Common stock warrants		666,667		0.0225			N/A		N/A
	Common stock warrants		1,000,000		0.025			N/A		N/A
	Common stock warrants		333,333		0.03			N/A		N/A
	Common stock warrants		2,000,001		0.035			N/A		N/A
	Common stock warrants		500,000		0.04			N/A		N/A
	Common stock warrants		333,333		0.045			N/A		N/A
	Common stock warrants		400,000		0.05			N/A		N/A
	Common stock warrants		2,181,819		0.055			N/A		N/A
	Common stock warrants		2,000,000		0.06			N/A		N/A
	Common stock warrants		4,269,838		0.0625			N/A		N/A
	Common stock warrants		571,429		0.07			N/A		N/A
	Common stock warrants		666,666		0.09			N/A		N/A
	Common stock warrants		416,667		0.12			N/A		N/A
	Common stock warrants		1,200,000		0.25			N/A		N/A
Common stock warrants		833,333		0.27			N/A		N/A
Common stock warrants		333,333		0.3			N/A		N/A
Common stock warrants		153,846		0.325			N/A		N/A
Common stock warrants		1,028,570		0.35			N/A		N/A
$10,000, 10% Convertible promissory note to related party		22,222		0.45			N/A		N/A
Convertible promissory notes		14,762,257		(1	)		N/A		N/A
Total		45,970,314
-1	The principal amount of convertible promissory notes outstanding at December 31, 2013, was $272,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.

Stock_Options_Tables

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2014
Stock Options [Abstract]
Summary of activity in company's stock option plan
			Exercise Price Per Share		Number Outstanding		Weighted Average Remaining Contractual Life	Number Exercisable		Weighted Average Exercise Price			Weighted Average Fair Value Per Stock Option at Date of Grant
	Balance, 1/1/13		$0.060 - $1.000		11,697,000		12	6,090,000		$	0.194		$	0.18
	Stock options granted		0.042		100,000		14	-			0.042			0.042
	Vested		0.06		-		13	5,607,000			0.06			0.064
	Balance, 12/31/13		0.042 – 1.000		11,797,000		12	11,697,000			0.193			0.179
	Stock options granted		0.028		703,000		15	-			0.028			0.028
	Vested		0.042		-		14	100,000			0.42			0.042
	Balance, 12/31/14		$0.028 – $1.000		12,500,000		12	11,707,000		$	0.184		$	0.169
Summary of assumptions used to determine weighted average fair value	●	Historical stock price volatility		139% - 325%
	●	Risk-free interest rate		0.21% - 4.64%
	●	Expected life (in years)		4
	●	Dividend yield		0
Summary of stock options outstanding	Name		Title		Number of Shares of Common Stock Underlying Stock Options			Exercise Price per Share				Option  Expiration  Date
	George J. Coates		Chairman, Chief  Executive			1,000,000	-1	$	0.44			10/23/21
			Officer and President			50,000	-1		0.43			11/4/24
						275,000	-1		0.4			11/17/25
						1,800,000	-1		0.25			7/25/26
						1,815,000	-1		0.06			6/24/27
	Gregory G. Coates		Director and President,			500,000	-1		0.44			10/23/21
			Technology Division			1,800,000	-1		0.24			8/8/26
						351,000	-2		0.028			4/30/29
	Barry C. Kaye		Director, Treasurer and			125,000	-1		0.44			10/18/21
			Chief Financial Officer			100,000	-1		0.042			12/11/28
						351,000	-2		0.028			4/30/29
	Dr. Frank J. Adipietro		Non-employee Director			25,000	-1		0.44			3/28/22
						50,000	-1		0.43			11/3/24
						85,000	-1		0.4			11/17/25
						667,000	-1		0.06			6/24/27
	Dr. Richard W. Evans		Non-employee Director and Secretary			25,000	-1		0.44			3/28/22
						50,000	-1		0.39			12/27/24
						200,000	-1		0.25			2/15/26
						3,125,000	-1		0.06			6/20/27
	Dr. Michael J. Suchar		Non-employee Director			25,000	-1		0.44			3/28/22
	Richard Whitworth		Non-employee Director			25,000	-1		0.44			3/28/22
	William Wolf. Esq.		Outside General Counsel			25,000	-1		0.44			4/4/22
	Company Supplier		Company Supplier			30,000	-1		1			10/7/15
	(1) These stock options are fully vested.
	(2) These options will fully vest in April 2015.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Schedule of total deferred tax assets and valuation allowances
		2014			2013
	Current deferred tax asset - inventory reserve	$	195,000		$	195,000
	Non-Current Deferred Tax Assets:
	Net operating loss carryforwards		6,475,000			6,201,000
	Stock-based compensation expense		4,242,000			1,688,000
	Accrued liabilities not paid		464,000			481,000
	Deferred compensation not paid within 2.5 months		432,000			115,000
	Accrued interest on notes to related parties		159,000			115,000
	Total long-term deferred tax assets		11,772,000			8,600,000
	Total deferred tax assets		11,967,000			8,795,000
	Less: valuation allowance		(11,967,000	)		(8,795,000	)
	Net deferred tax assets	$	-		$	-
Schedule of differences in Income tax (benefit) provision
		2014			2013
	Federal tax provision at the statutory rate		34	%		34	%
	State income tax provision (benefit), net of federal benefit		(2.2	)		(2.7	)
	Stock-based compensation expense		(20.0	)		(9.1	)
	Deferred compensation not paid within 2.5 months		(2.5	)		(4.2	)
	Accrued interest not deductible for tax return purposes		(2.5	)		(6.0	)
	Net change in net operating loss carryforwards		(2.1	)		(15.5	)
	Increase in estimated fair value of embedded derivative liabilities		(0.3	)		(3.1	)
	Accrued liabilities not deductible for tax return purposes		0.3			0.4
	Officer’s life insurance		(0.0	)		(0.2	)
	Total		(4.7	)		(6.4	)
	Valuation allowance		4.7			6.4
	Effective tax rate		0	%		0	%

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Summary of approximate amount of base compensation and benefits
			For the Year Ended,
			2014		2013
		George J. Coates (a) (b) (c) (d) (e) (f) (g)	$	16,000	$	29,000
		Gregory G. Coates (h) (i)		177,000		169,000
		Bernadette Coates (j)		4,000		15,000

Contractual_Obligations_and_Co1

Contractual Obligations and Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Contractual Obligations and Commitments / Litigation and Contingencies [Abstract]
Summary of contractual obligations and commitments				Due Within
		Total		2015		2016
	Promissory notes to related parties	$	1,566,000	$	1,566,000	$	-
	Mortgage loan payable		1,448,000		1,448,000		-
	Deferred compensation		1,080,000		1,080,000		-
	Convertible promissory notes		696,000		576,000		120,000
	Finance lease obligation		94,000		72,000		22,000
	Settlement of litigation		10,000		10,000		-
	Total	$	4,894,000	$	4,752,000	$	142,000

The_Company_and_Summary_of_Sig3

The Company and Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
The Company and Summary of Significant Accounting Policies [Abstract]
Issuance of convertible promissory notes	$995,583	$398,000
Proceeds from sale of stock and warrants to the son of director	515,000	125,000
Deposit on non-exclusive distribution license with China-based company	498,000
Sales of common stock under equity line of credit	161,636	155,506
Proceeds from exercise of common stock warrants	10,000	10,000
Proceeds from sale/leaseback of equipment		132,550
Issuances of promissory notes to related parties, net of repayments		95,000
New working capital	$2,181,000	$917,000

The_Company_and_Summary_of_Sig4

The Company and Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
The Company and Summary of Significant Accounting Policies (Textual)
Stockholder's deficiency	($5,433,529)	($3,231,617)	($3,937,287)
Negative working capital	-7,296,000	-5,078,000
Research and development expenses	115,000	115,000
Mortgage loan maturity date	31-Jul-15
Mortgage Loans on Real estate, extended, amount	1,448,000
New working capital	2,181,000	917,000
Marketing and advertising expense	45,000
Advertising Expense	48,000	3,000
License Deposits [Member]
The Company and Summary of Significant Accounting Policies (Textual)
License Deposits	$300,000
Term Of Sublicense Deposit	Straight-line basis over the approximate remaining life through 2027 of the last CSRV® technology patent in force.
Building and Building Improvements [Member]
The Company and Summary of Significant Accounting Policies (Textual)
Estimated useful life of the assets	40 years
Machinery and Equipment [Member] | Maximum [Member]
The Company and Summary of Significant Accounting Policies (Textual)
Estimated useful life of the assets	7 years
Machinery and Equipment [Member] | Minimum [Member]
The Company and Summary of Significant Accounting Policies (Textual)
Estimated useful life of the assets	3 years
Furniture and Fixtures [Member] | Maximum [Member]
The Company and Summary of Significant Accounting Policies (Textual)
Estimated useful life of the assets	10 years
Furniture and Fixtures [Member] | Minimum [Member]
The Company and Summary of Significant Accounting Policies (Textual)
Estimated useful life of the assets	5 years

Concentrations_of_Credit_and_B1

Concentrations of Credit and Business Risk (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Concentrations of Credit and Business Risk [Abstract]
Deposits in other financial institutions	$213,000
Percentage of funds invested in bank certificates of deposit, asset backed commercial paper and government agency debt securities	93.00%

Licensing_Agreement_and_Deferr1

Licensing Agreement and Deferred Licensing Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Licensing Agreement and Deferred Licensing Costs (Textual)
Deferred licensing costs	$47,000	$51,000
Amortization expense	$4,000	$4,000

Agreements_Assigned_to_Almont_1

Agreements Assigned to Almont Energy, Inc. (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
	Units
Agreements Assigned to Almont Energy, Inc. (Textual)
Release payment extended date	19-Mar-14
Percentage of money raised required to remit from future equity or debt transactions by Almont Energy	60.00%
Percentage of quarterly net profits payable	5.00%
Units projected to be purchased per year over next 5 years	11,000
Canadian License [Member]
Agreements Assigned to Almont Energy, Inc. (Textual)
License fee amount	5,000,000
Additional fee under R&D Agreement	5,000,000
Percentage of modified gross profit to be paid	5.00%
Adjustment to basis for Royalty revenue	400,000
Minimum annual number of generators to be purchased	120
Price per generator	159,000
Us License [Member]
Agreements Assigned to Almont Energy, Inc. (Textual)
License fee amount	50,000,000
Down payment receivable under Escrow Agreement	1,000,000
Remaining balance of release payment	5,847,000
License fee due date	19-Feb-16
Obligation under license fee	49,000,000
Percentage of modified gross profit to be paid	2.50%
Adjustment to basis for Royalty revenue	400,000
Minimum annual number of internal combustion engines	120

Proposed_NonExclusive_Distribu1

Proposed Non-Exclusive Distribution Sublicense with Renown Power Development, Ltd. (Details) (Renown Power Development, Ltd [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Renown Power Development, Ltd [Member]
Proposed Distribution Sublicense Agreement and Separate License Agreement With Renown Power Development, Ltd (Textual)
licensing fee	$100,000,000
Non-Refundable Deposit	500,000
Tentative terms of agreement, Description	The tentative terms of the agreement would provide that after Renown receives an aggregate of US$10,000,000, it would be required to pay the Company 25% of all funds it receives from any and all sources until the entire US$100 million licensing fee is paid in full. In the event, that Renown completes one or more capital raises aggregating US$300 million or more, the then remaining unpaid balance of the US$100 million licensing fee would become immediately due and payable
Outstanding licensing fee	100,000,000
Aggregate amount of capital raises to trigger immediate payment of balance of licensing fee	$300,000,000

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary of inventory
Raw materials	$381,000	$440,000
Work-in-process	53,000	59,000
Finished goods
Less: Reserve for obsolescence	-387,000	-387,000
Total	$47,000	$112,000

License_Deposits_Details

License Deposits (Details) (License Deposits [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
License Deposits [Member]
License Deposits (Textual)
License deposit recognition term	Straight-line basis over the approximate remaining life through 2027 of the last CSRV® technology patent in force.
Sublicensing fee revenue	$19,000	$19,000
Refundable good faith deposit	498,000
Non Refundable Deposit	$20,000

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary of Property, plant and equipment
Property, plant and equipment, Gross	$2,979,000	$2,979,000
Less: Accumulated depreciation	-860,000	-799,000
Total	2,119,010	2,179,646
Land [Member]
Summary of Property, plant and equipment
Property, plant and equipment, Gross	1,235,000	1,235,000
Building [Member]
Summary of Property, plant and equipment
Property, plant and equipment, Gross	964,000	964,000
Building Improvements [Member]
Summary of Property, plant and equipment
Property, plant and equipment, Gross	83,000	83,000
Machinery and Equipment [Member]
Summary of Property, plant and equipment
Property, plant and equipment, Gross	658,000	658,000
Furniture and Fixtures [Member]
Summary of Property, plant and equipment
Property, plant and equipment, Gross	$39,000	$39,000

Property_Plant_and_Equipment_D1

Property, Plant and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment (Textual)
Depreciation expense	$61,000	$62,000

Mortgage_Loan_Payable_Details

Mortgage Loan Payable (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Mortgage Loan Payable (Textual)
Maturity Date	1-Jul-15
Mortgage loan payable, interest rate	7.50%
Interest expense	$121,000	$114,000
Mortgage loan payment terms	Monthly payments of interest, plus $5,000 which is being applied to the principal balance.
Periodic payment of principal	5,000
Principal balance of mortgage loan due	1,448,000
Maximum prepayment of mortgage loan without penalty	$500,000
Percentage of prepayment penalty on outstanding loan amount	2.00%
Number of shares pledged as collateral	5 million

Finance_Lease_Obligation_Detai

Finance Lease Obligation (Details) (Finance Lease Obligations [Member], USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Finance Lease Obligation (Textual)
Deposits on lease	$15,000
Transaction costs	5,000
Equipment, lease back period		Over a 24-month period, with an option to extend the lease for an additional six months.
Monthly lease payment	8,000
Effective Interest rate on lease	36.60%
Unamortized discount on finance lease obligation	20,000
Amortization period of discount		Over the 30-month term of the lease.
Financial lease, interest expense		51,000	21,000
Paradigm Commercial Capital Group Corp [Member]
Finance Lease Obligation (Textual)
Cash proceeds for research and development and manufacturing equipment	$133,000

Accounts_Payable_and_Accrued_L2

Accounts Payable and Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary of accounts payable and accrued liabilities
Legal and professional fees	$1,290,000	$1,388,000
Accrued interest expense	374,000	264,000
General and administrative expenses	194,000	301,000
Research and development costs	115,000	115,000
Accrued compensation and benefits	10,000	196,000
Total	$1,983,000	$2,264,000

Promissory_Notes_to_Related_Pa1

Promissory Notes to Related Parties (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Apr. 29, 2014	30-May-14
Promissory Notes to Related Parties (Textual)
Promissory notes, interest rate	17.00%
Promissory notes interest expense	$112,000	$130,000
Promissory notes unpaid accrued interest	342,000
Conversion of additional paid-in capital to promissory note to related party	1,462,093
George J. Coates [Member]
Promissory Notes to Related Parties (Textual)
Cash proceeds from related party promissory notes		105,000
Repaid promissory notes principal amount	200,000	67,000
Promissory notes, interest rate	17.00%
Promissory Note to Related Party Converted to Common Stock	950,000
Bernadette Coates [Member]
Promissory Notes to Related Parties (Textual)
Cash proceeds from related party promissory notes		68,000
Repaid promissory notes principal amount	80,000	10,000
Promissory notes, interest rate	17.00%
Gregory G. Coates [Member]
Promissory Notes to Related Parties (Textual)
Conversion of additional paid-in capital to promissory note to related party			1,462,000
Mr. Coates [Member]
Promissory Notes to Related Parties (Textual)
Promissory notes, interest rate			17.00%
Promissory Note to Related Party Converted to Common Stock			950,000	370,000
Interest bearing on demand loan converted to common stock			50,000
Recission of conversion of promissory note converted to common stock				200,000
Conversion price per share of debt converted			$0.03	$0.03
Number of shares of common stock issued upon conversion of promissory notes to related parties			39,682,540	6,896,552
Common Stock Dilution Description			The percentage of the Company owned by non-affiliate shareholders decreased from 32.9% to 29.5% of the outstanding common stock of the Company.
Decrease in current liabilities				170,000
Estimated decrease in annual Interest expense				$29,000

10_Convertible_Note_to_Related1

10% Convertible Note to Related Party (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
10% Note to Related Party [Abstract]
Interest Rate	17.00%
Michael J Suchar [Member]
10% Note to Related Party [Abstract]
Interest Rate	10.00%
Conversion price	$0.03
Restricted shares of common stock issued	612,664
Amount of Note Converted, including accrued interest	$17,000

Convertible_Promissory_Notes_a2

Convertible Promissory Notes and Embedded Derivative Liability (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Debt Instrument [Line Items]
Debt instrument principal amount issued	$696,000		$272,000
Nominal Interest Rate	17.00%
Embedded Derivative Liability	476,000		367,000
Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount issued	996,000		398,000
Unamortized Discount	195,000		147,000
12/16/14 [Member]
Debt Instrument [Line Items]
Date Issued	16-Dec-14
Debt instrument principal amount issued	28,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	55.00%	[1]
Conversion price	40.00%
Unamortized Discount	8,000
Embedded Derivative Liability	31,000
12/5/14 [Member]
Debt Instrument [Line Items]
Date Issued	5-Dec-14
Debt instrument principal amount issued	53,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	160.00%	[1]
Conversion price	39.00%
Unamortized Discount	42,000
Embedded Derivative Liability	20,000
11/25/14 [Member]
Debt Instrument [Line Items]
Date Issued	25-Nov-14
Debt instrument principal amount issued	52,000
Nominal Interest Rate	9.75%
Effective Interest Rate(1)	91.00%	[1]
Conversion price	30.00%
Unamortized Discount	24,000
Embedded Derivative Liability	41,000
11/14/14 [Member]
Debt Instrument [Line Items]
Date Issued	14-Nov-14
Debt instrument principal amount issued	40,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	139.00%	[1]
Conversion price	32.50%
Unamortized Discount	30,000
Embedded Derivative Liability	54,000
10/2/14 [Member]
Debt Instrument [Line Items]
Date Issued	2-Oct-14
Debt instrument principal amount issued	40,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	113.00%	[1]
Conversion price	35.00%
Unamortized Discount	16,000
Embedded Derivative Liability	43,000
9/29/14 [Member]
Debt Instrument [Line Items]
Date Issued	29-Sep-14
Debt instrument principal amount issued	53,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	118.00%	[1]
Conversion price	39.00%
Unamortized Discount	29,000
Embedded Derivative Liability	20,000
9/3/14 [Member]
Debt Instrument [Line Items]
Date Issued	3-Sep-14
Debt instrument principal amount issued	39,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	139.00%	[1]
Conversion price	40.00%
Unamortized Discount	15,000
Embedded Derivative Liability	38,000
8/29/14 [Member]
Debt Instrument [Line Items]
Date Issued	29-Aug-14
Debt instrument principal amount issued	53,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	105.00%	[1]
Conversion price	39.00%
Unamortized Discount	13,000
Embedded Derivative Liability	17,000
8/8/14 [Member]
Debt Instrument [Line Items]
Date Issued	8-Aug-14
Debt instrument principal amount issued	52,000
Nominal Interest Rate	9.75%
Effective Interest Rate(1)	72.00%	[1]
Conversion price	30.00%
Unamortized Discount	5,000
Embedded Derivative Liability	41,000
7/28/14 [Member]
Debt Instrument [Line Items]
Date Issued	28-Jul-14
Debt instrument principal amount issued	30,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	156.00%	[1]
Conversion price	30.00%
Unamortized Discount	6,000
Embedded Derivative Liability	25,000
7/9/14 [Member]
Debt Instrument [Line Items]
Date Issued	9-Jul-14
Debt instrument principal amount issued	83,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	120.00%	[1]
Conversion price	39.00%
Unamortized Discount	5,000
Embedded Derivative Liability	15,000
7/8/14 [Member]
Debt Instrument [Line Items]
Date Issued	8-Jul-14
Debt instrument principal amount issued	50,000
Nominal Interest Rate	5.00%
Effective Interest Rate(1)	106.00%	[1]
Conversion price	37.00%
Unamortized Discount	2,000
Embedded Derivative Liability	31,000
6/12/14 [Member]
Debt Instrument [Line Items]
Date Issued	12-Jun-14
Debt instrument principal amount issued	47,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	147.00%	[1]
Conversion price	40.00%
Unamortized Discount
Embedded Derivative Liability	46,000
4/16/14 [Member]
Debt Instrument [Line Items]
Date Issued	16-Apr-14
Debt instrument principal amount issued	25,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	147.00%	[1]
Conversion price	30.00%
Unamortized Discount
Embedded Derivative Liability	17,000
4/16/14 [Member]
Debt Instrument [Line Items]
Date Issued	16-Apr-14
Debt instrument principal amount issued	24,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	175.00%	[1]
Conversion price	40.00%
Unamortized Discount
Embedded Derivative Liability	15,000
4/2/14 [Member]
Debt Instrument [Line Items]
Date Issued	2-Apr-14
Debt instrument principal amount issued	27,000
Nominal Interest Rate	9.75%
Effective Interest Rate(1)	71.00%	[1]
Conversion price	30.00%
Unamortized Discount
Embedded Derivative Liability	22,000
12/11/13 [Member]
Debt Instrument [Line Items]
Date Issued	11-Dec-13
Debt instrument principal amount issued			28,000
Nominal Interest Rate	10.00%
Effective Interest Rate(1)	134.00%	[1]
Conversion price	42.00%
Unamortized Discount			22,000
Embedded Derivative Liability			43,000
12/10/13 [Member]
Debt Instrument [Line Items]
Date Issued	10-Dec-13
Debt instrument principal amount issued			28,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	117.00%	[1]
Conversion price	40.00%
Unamortized Discount			19,000
Embedded Derivative Liability			45,000
12/9/13 [Member)
Debt Instrument [Line Items]
Date Issued	9-Dec-13
Debt instrument principal amount issued			28,000
Nominal Interest Rate	10.00%
Effective Interest Rate(1)	134.00%	[1]
Conversion price	42.00%
Unamortized Discount			22,000
Embedded Derivative Liability			43,000
11/27/13 [Member)
Debt Instrument [Line Items]
Date Issued	27-Nov-13
Debt instrument principal amount issued			32,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	133.00%	[1]
Conversion price	39.00%
Unamortized Discount			25,000
Embedded Derivative Liability			33,000
10/11/13 (Member)
Debt Instrument [Line Items]
Date Issued	11-Oct-13
Debt instrument principal amount issued			47,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	147.00%	[1]
Conversion price	39.00%
Unamortized Discount			31,000
Embedded Derivative Liability			48,000
8/14/13 [Member]
Debt Instrument [Line Items]
Date Issued	14-Aug-13
Debt instrument principal amount issued			28,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	147.00%	[1]
Conversion price	40.00%
Unamortized Discount			14,000
Embedded Derivative Liability			45,000
8/8/13 [Member]
Debt Instrument [Line Items]
Date Issued	8-Aug-13
Debt instrument principal amount issued			53,000
Nominal Interest Rate	8.00%
Effective Interest Rate(1)	147.00%	[1]
Conversion price	39.00%
Unamortized Discount			14,000
Embedded Derivative Liability			53,000
6/4/13 [Member]
Debt Instrument [Line Items]
Date Issued	4-Jun-13
Debt instrument principal amount issued			28,000
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	92.00%	[1]
Conversion price	40.00%
Unamortized Discount
Embedded Derivative Liability			45,000
3/21/13 [Member]
Debt Instrument [Line Items]
Date Issued	21-Mar-13
Debt instrument principal amount issued
Nominal Interest Rate	12.00%
Effective Interest Rate(1)	76.00%	[1]
Conversion price	40.00%
Unamortized Discount
Embedded Derivative Liability			$12,000
[1]	The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.

Convertible_Promissory_Notes_a3

Convertible Promissory Notes and Embedded Derivative Liability (Details Textual) (USD $)	2 Months Ended	12 Months Ended
	31-May-14	Dec. 31, 2014	Dec. 31, 2013
Convertible Promissory Notes and Embedded Derivative Liabilities (Textual)
Debt instrument principal amount issued		$696,000	$272,000
Conversion of promissory notes		237,187
Convertible Promissory Notes [Member]
Convertible Promissory Notes and Embedded Derivative Liabilities (Textual)
Debt instrument principal amount issued		996,000	398,000
Conversion price, description		The notes may be converted into unregistered shares of the Company's common stock at a discount ranging from 30% to 42% of the defined trading price of the common stock on the date of conversion. The defined trading prices are based on the trading price of the stock during a defined period ranging from ten to twenty-five trading days immediately preceding the date of conversion.
Common shares issued upon conversion of debt	14,733,289	48,251,621	13,718,349
Other (expense) income resulting from the change in the estimated fair value of the embedded derivative liabilities		104,000	210,000
Interest expense resulting from accretion of the unamortized discount		697,000	283,000
Common shares reserved for future conversion of debt		263,703,000
Prepayment option, description		All of the convertible notes become convertible, in whole, or in part, beginning on the six month anniversary of the issuance date and may be prepaid at the option of the Company, generally with a prepayment penalty of from 25% to 50% of the principal amount of the convertible note at any time prior to becoming eligible for conversion.
Conversion of promissory notes		627,000	271,000
Convertible Promissory Notes [Member] | Maximum [Member]
Convertible Promissory Notes and Embedded Derivative Liabilities (Textual)
Conversion rate		42.00%
Convertible Promissory Notes [Member] | Minimum [Member]
Convertible Promissory Notes and Embedded Derivative Liabilities (Textual)
Conversion rate		30.00%
One Convertible Promissory Note [Member]
Convertible Promissory Notes and Embedded Derivative Liabilities (Textual)
Debt instrument principal amount issued		$132,000
Conversion price, description		This convertible note also requires that the conversion price be re-measured 23 trading days after the conversion shares are originally delivered. If the re-measured conversion price is lower, then the Company is required to issue additional conversion shares to the noteholder.
Number of convertible promissory notes		1

Capital_Stock_Details

Capital Stock (Details) (USD $)	12 Months Ended		1 Months Ended	2 Months Ended	1 Months Ended	12 Months Ended		0 Months Ended	6 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	31-May-14	Jan. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 01, 2014	Jul. 02, 2014	Jul. 28, 2014	Jul. 03, 2014	Dec. 31, 2002
Capital Stock (Textual)
Common stock, authorized shares	1,000,000,000	1,000,000,000
Common stock , par value	$0.00	$0.00
Unregistered shares of common stock issued upon exercise of warrants	500,000	666,667
Proceeds from sale of stock and warrants to the son of director	$515,000	$125,000
Proceeds from sales of common stock under equity line of credit	161,636	155,506
Debt conversion converted instrument amount	626,785	271,056
Fair value of stock issued	8,070,000
Common stock shares, reserved for convertible instruments	312,047,911
Preferred stock, authorized shares	100,000,000	100,000,000
Preferred stock, par value	$0.00	$0.00
Total non-cash, stock-based compensation expense arising from issuance of shares of Series A Preferred Stock	10,174,258	634,938
Series A Preferred Stock [Member]
Capital Stock (Textual)
Preferred stock, authorized shares	100,000,000	100,000,000
Preferred stock, issued shares	50,000	141,473
Preferred stock, outstanding shares	50,000	141,473
Preferred stock, par value	$0.00	$0.00
Description of preferred stock voting rights	Shares of Series A entitle the holder to 10,000 votes per share on all matters brought before the shareholders for a vote.
Series B Preferred Stock [Member]
Capital Stock (Textual)
Number of shares of common stock underlying outstanding shares of Series B Convertible Preferred Stock	585,502,000
Number of shares of common stock into which each share of Series B Peferred Stock is convertible	1,000
Preferred stock, authorized shares	1,000,000	1,000,000
Preferred stock, issued shares	585,502	0
Preferred stock, outstanding shares	585,502	0
Preferred stock, par value	$0.00	$0.00
Preferred stock value outstanding	8,721,000
Percentage of non - affiliate shareholder ownership before assumed conversion	35.70%
Percentage of non - affiliate shareholder ownership after assumed conversion	15.30%
Description of preferred stock voting rights	Holders of the Series B are entitled to one thousand votes per share held on all matters brought before the shareholders for a vote.
17% promissory notes [Member]
Capital Stock (Textual)
Principal amount of debt, converted into shares of common stock			200,000	420,000
Conversion price per share of debt converted				$0.03
Common shares issued upon conversion of debt	48,251,621	13,718,349		14,733,289
Number of shares of common stock returned upon recission of debt conversion			6,896,552
Promissory notes one [Member]
Capital Stock (Textual)
Principal amount of debt, converted into shares of common stock	950,000
Conversion price per share of debt converted	$0.03
Common shares issued upon conversion of debt	37,698,413
Convertible Promissory Notes [Member]
Capital Stock (Textual)
Unregistered shares of common stock issued	48,251,621	13,718,349
Principal amount of debt, converted into shares of common stock	627,000	271,000
George J. Coates [Member]
Capital Stock (Textual)
Unregistered shares of common stock issued		14,142,085			20,895,046
Stock award granted						20,275,046	620,000
Fair value of stock issued		430,000
Estimated fair value of anit-dilution shares granted and stock awarded in 2012 and 2011					1,761,000	1,674,000	87,000
Ownership percentage										5.31%
Total non-cash, stock-based compensation expense arising from issuance of shares of Series A Preferred Stock	169,000	170,000
George J. Coates [Member] | Series A Preferred Stock [Member]
Capital Stock (Textual)
Fair value of stock issued								69,000
Shares of Series A Preferred Stock issued		68,590						50,000	40,191
Preferred stock, outstanding shares	50,000
Preferred stock, par value											0.001
Description of preferred stock voting rights	Mr. Coates held all 50,000 shares of Series A outstanding, which entitle him to 500 million votes in addition to his voting rights from the shares of common stock and the shares of Series B he holds.
Shares of Series A preferred stock converted into series B convertible preferred stock											181,664
George J. Coates [Member] | Series B Preferred Stock [Member]
Capital Stock (Textual)
Shares of Series A Preferred Stock issued										115,006	75,000
Preferred stock, outstanding shares	541,933
Ownership percentage												78.00%
Gregory G. Coates [Member] | Series B Preferred Stock [Member]
Capital Stock (Textual)
Preferred stock, outstanding shares	40,593
Son Of Director [Member]
Capital Stock (Textual)
Unregistered shares of common stock issued	16,456,076	4,666,666
Warrants sold to purchase one share of common stock	16,456,076	5,566,668
Exercise price of warrants exercised	$0.02	$0.02
Proceeds from sale of stock and warrants to the son of director	10,000	10,000
Dutchess [Member]
Capital Stock (Textual)
Registered shares of common stock issued for sales under equity line of credit	4,403,403	3,618,676
Proceeds from sales of common stock under equity line of credit	162,000	156,000
Michael J Suchar [Member]
Capital Stock (Textual)
Conversion price per share of debt converted	$0.03
Number of shares of common stock issued upon conversion of debt	612,664
Debt conversion converted instrument amount	$17,000
Barry C Kaye [Member]
Capital Stock (Textual)
Ownership percentage										0.04%
Barry C Kaye [Member] | Series B Preferred Stock [Member]
Capital Stock (Textual)
Preferred stock, outstanding shares	2,976
Accredited Investors [Member]
Capital Stock (Textual)
Number of accredited investors	8
Minimum [Member] | 17% promissory notes [Member]
Capital Stock (Textual)
Discount as defined for trading price of convertible debt	30.00%
Minimum [Member] | Son Of Director [Member]
Capital Stock (Textual)
Exercise price of warrants exercised	$0.02	$0.02
Maximum [Member] | 17% promissory notes [Member]
Capital Stock (Textual)
Discount as defined for trading price of convertible debt	42.00%
Maximum [Member] | Son Of Director [Member]
Capital Stock (Textual)
Exercise price of warrants exercised	$0.04	$0.04

Unearned_Revenue_Details

Unearned Revenue (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Unearned Revenue [Abstract]
Unearned revenue	$19,124	$19,124

Sublicensing_Fee_Revenue_Detai

Sublicensing Fee Revenue (Details) (Sublicensing Fee Revenue [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Sublicensing Fee Revenue [Member]
Sublicensing Fee Revenue [Line Items]
Sublicensing fee revenue	$19,000	$19,000
Sublicense deposit received as down payment on Canadian License	$300,000
Amortization method, description	Straight-line basis over the approximate remaining life of last to expire patent until 2027

Employee_Compensation_and_Bene1

Employee Compensation and Benefits (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Employee Compensation and benefits	$10,400,971	$1,047,283
Non-cash stock-based compensation expense	10,174,258	634,938
Employee benefits of salaries and wages	227,000	433,000
George J. Coates and Bernadette Coates [Member]
Related Party Transaction [Line Items]
Unpaid salaries	$317,000	$288,000

Income_Loss_Per_Share_Details

Income (Loss) Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	176,919,302		14,762,257
Number Non-Vested	703,000
Common stock options 1 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	703,000		100,000
Exercise Price	0.028		0.042
Number Vested
Number Non-Vested	703,000		100,000
Common stock options 2 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	100,000		5,607,000
Exercise Price	0.042		0.06
Number Vested	100,000		5,607,000
Number Non-Vested
Common stock options 3 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	5,607,000		1,800,000
Exercise Price	0.06		0.24
Number Vested	5,607,000		1,800,000
Number Non-Vested
Common stock options 4 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	1,800,000		2,000,000
Exercise Price	0.24		0.25
Number Vested	1,800,000		2,000,000
Number Non-Vested
Common stock options 5 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	2,000,000		50,000
Exercise Price	0.25		0.39
Number Vested	2,000,000		50,000
Number Non-Vested
Common stock options 6 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	50,000		360,000
Exercise Price	0.39		0.4
Number Vested	50,000		360,000
Number Non-Vested
Common stock options 7 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	360,000		100,000
Exercise Price	0.4		0.43
Number Vested	360,000		100,000
Number Non-Vested
Common stock options 8 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	100,000		1,750,000
Exercise Price	0.43		0.44
Number Vested	100,000		1,750,000
Number Non-Vested
Common stock options 9 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	1,750,000		30,000
Exercise Price	0.44		1
Number Vested	1,750,000		30,000
Number Non-Vested
Common stock options 10 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	30,000
Exercise Price	1
Number Vested	30,000
Number Non-Vested
Common stock warrants 1 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	1,750,000		500,000
Exercise Price	0.02		0.02
Number Vested
Number Non-Vested
Common stock warrants 2 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	666,667		666,667
Exercise Price	0.0225		0.0225
Number Vested
Number Non-Vested
Common stock warrants 3 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	2,127,660		1,000,000
Exercise Price	0.0235		0.025
Number Vested
Number Non-Vested
Common stock warrants 4 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	5,000,000		333,333
Exercise Price	0.025		0.03
Number Vested
Number Non-Vested
Common stock warrants 5 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	1,739,130		2,000,001
Exercise Price	0.02875		0.035
Number Vested
Number Non-Vested
Common stock warrants 6 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	333,333		500,000
Exercise Price	0.03		0.04
Number Vested
Number Non-Vested
Common stock warrants 7 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	2,714,287		333,333
Exercise Price	0.035		0.045
Number Vested
Number Non-Vested
Common stock warrants 8 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	7,125,000		400,000
Exercise Price	0.04		0.05
Number Vested
Number Non-Vested
Common stock warrants 9 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	333,333		2,181,819
Exercise Price	0.045		0.055
Number Vested
Number Non-Vested
Common stock warrants 10 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	400,000		2,000,000
Exercise Price	0.05		0.06
Number Vested
Number Non-Vested
Common stock warrants 11 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	2,181,819		4,269,838
Exercise Price	0.055		0.0625
Number Vested
Number Non-Vested
Common stock warrants 12 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	171,428		571,429
Exercise Price	0.057		0.07
Number Vested
Number Non-Vested
Common stock warrants 13 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	285,714		666,666
Exercise Price	0.0581		0.09
Number Vested
Number Non-Vested
Common stock warrants 14 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	428,571		416,667
Exercise Price	0.0585		0.12
Number Vested
Number Non-Vested
Common stock warrants 15 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	2,000,000		1,200,000
Exercise Price	0.06		0.25
Number Vested
Number Non-Vested
Common stock warrants 16 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	4,269,838		833,333
Exercise Price	0.0625		0.27
Number Vested
Number Non-Vested
Common stock warrants 17 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	333,333		333,333
Exercise Price	0.0675		0.3
Number Vested
Number Non-Vested
Common stock warrants 18 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	571,429		153,846
Exercise Price	0.07		0.325
Number Vested
Number Non-Vested
Common stock warrants 19 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	666,666		1,028,570
Exercise Price	0.09		0.35
Number Vested
Number Non-Vested
Common stock warrants 20 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	416,667
Exercise Price	0.12
Number Vested
Number Non-Vested
Common stock warrants 21 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	1,200,000
Exercise Price	0.25
Number Vested
Number Non-Vested
Common stock warrants 22 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	833,333
Exercise Price	0.27
Number Vested
Number Non-Vested
Common stock warrants 23 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	153,846
Exercise Price	0.325
Number Vested
Number Non-Vested
Common stock warrants 24 [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	142,857
Exercise Price	0.35
Number Vested
Number Non-Vested
$10,000, 10% Convertible promissory note to related party Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock			22,222
Exercise Price			0.45
Number Vested
Number Non-Vested
Convertible promissory notes [Member]
Trading Securities [Abstract]
Number of Underlying Shares of Common Stock	128,574,391		14,762,257
Exercise Price		[1]		[2]
Number Vested
Number Non-Vested
[1]	The principal amount of convertible promissory notes outstanding at December 31, 2014, was $696,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2014.
[2]	The principal amount of convertible promissory notes outstanding at December 31, 2013, was $272,000. Under the convertible terms of these notes, the number of share of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading price of the common stock over a defined a number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of December 31, 2013.

Income_Loss_Per_Share_Details_

Income (Loss) Per Share (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income (Loss) Per Share Textual [Abstract]
Convertible promissory notes outstanding eligible for conversion	$696,000	$272,000
Promissory notes, interest rate	17.00%
$10,000, 10% Convertible promissory note to related party Member]
Income (Loss) Per Share Textual [Abstract]
Convertible promissory notes outstanding eligible for conversion		$10,000
Promissory notes, interest rate		10.00%

Stock_Options_Details

Stock Options (Details) (Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of common stock options outstanding under Stock Option Plan
Exercise price range per share, Stock options granted	$0.03	$0.04
Exercise Price Per Share Vested	0.042	0.06
Number Outstanding, Beginning balance	11,797,000	11,697,000
Number Outstanding ,Stock option granted	703,000	100,000
Number Outstanding, Ending balance	12,500,000	11,797,000
Weighted Average Remaining Contractual Life, Beginning Balance	12 years	12 years
Weighted Average Remaining Contractual Life, Stock options granted	15 years	14 years
Weighted Average Remaining Contractual Life, Vested	14 years	13 years
Weighted Average Remaining Contractual Life, Ending Balance	12 years	12 years
Number Exercisable, Beginning balance	11,697,000	6,090,000
Number exercisable,Stock options granted
Number Exercisable, Vested	100,000	5,607,000
Number Exercisable, Ending balance	11,707,000	11,697,000
Weighted Average Exercise Price, Beginning balance	$0.19	$0.19
Weighted average exercise price, Stock option granted	$0.03	$0.04
Weighted Average Exercise Price, stock option vested	$0.42	$0.06
Weighted Average Exercise Price, Ending balance	$0.18	$0.19
Weighted Average Fair Value Per Stock Option at Date of Grant, Beginning balance	$0.18	$0.18
Weighted Average Fair Value Per Stock Option at Date of Granted	$0.03	$0.04
Weighted Average Fair Value Per Stock Option at Date of Grant, Vested	$0.04	$0.06
Weighted Average Fair Value Per Stock Option at Date of Grant, Ending balance	$0.17	$0.18
Maximum [Member]
Summary of common stock options outstanding under Stock Option Plan
Exercise price range per share beginning balance			$1
Exercise price range per share ending balance	$1	$1	$1
Minimum [Member]
Summary of common stock options outstanding under Stock Option Plan
Exercise price range per share beginning balance			$0.06
Exercise price range per share ending balance	$0.03	$0.04	$0.06

Stock_Options_Details_1

Stock Options (Details 1)	12 Months Ended
	Dec. 31, 2014
Summary of assumptions used to determine weighted average fair value
Historical stock price volatility, minimum	139.00%
Historical stock price volatility, maximum	325.00%
Risk-free interest rate, minimum	0.21%
Risk-free interest rate, maximum	4.64%
Expected life (in years)	4 years
Dividend yield	0.00%

Stock_Options_Details_2

Stock Options (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	703,000		100,000
Exercise Price per share	$0.03		$0.04
Company Supplier [Member] | 10/7/2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	30,000	[1]
Exercise Price per share	$1
George J. Coates [Member] | 10/23/2021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	1,000,000	[1]
Exercise Price per share	$0.44
George J. Coates [Member] | 11/4/2024
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	50,000	[1]
Exercise Price per share	$0.43
George J. Coates [Member] | 11/17/2025
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	275,000	[1]
Exercise Price per share	$0.40
George J. Coates [Member] | 7/25/2026
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	1,800,000	[1]
Exercise Price per share	$0.25
George J. Coates [Member] | 6/24/2027
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	1,815,000	[1]
Exercise Price per share	$0.06
Gregory G. Coates [Member] | 10/23/2021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	500,000	[1]
Exercise Price per share	$0.44
Gregory G. Coates [Member] | 8/8/2026
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	1,800,000	[1]
Exercise Price per share	$0.24
Gregory G. Coates [Member] | 4/30/2029
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	351,000	[2]
Exercise Price per share	$0.03
Barry C. Kaye [Member] | 10/18/2021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	125,000	[1]
Exercise Price per share	$0.44
Barry C. Kaye [Member] | 12/11/2028
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	100,000	[1]
Exercise Price per share	$0.04
Barry C. Kaye [Member] | 4/30/2029
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Employees	351,000	[2]
Exercise Price per share	$0.03
Dr. Frank J. Adipietro [Member] | 3/28/2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Price per share	$0.44
Dr. Frank J. Adipietro [Member] | 11/3/2024
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	50,000	[1]
Exercise Price per share	$0.43
Dr. Frank J. Adipietro [Member] | 11/17/2025
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	85,000	[1]
Exercise Price per share	$0.40
Dr. Frank J. Adipietro [Member] | 6/24/2027
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	667,000	[1]
Exercise Price per share	$0.06
Dr. Richard W. Evans [Member] | 3/28/2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Price per share	$0.44
Dr. Richard W. Evans [Member] | 12/27/2024
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	50,000	[1]
Exercise Price per share	$0.39
Dr. Richard W. Evans [Member] | 2/15/2026
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	200,000	[1]
Exercise Price per share	$0.25
Dr. Richard W. Evans [Member] | 6/20/2027
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	3,125,000	[1]
Exercise Price per share	$0.06
Dr. Michael J. Suchar [Member] | 3/28/2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Price per share	$0.44
Richard Whitworth [Member] | 3/28/2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Price per share	$0.44
William Wolf. Esq. [Member] | 4/4/2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Shares of Common Stock Underlying Stock Options, Non-employees	25,000	[1]
Exercise Price per share	$0.44
[1]	These stock options are fully vested.
[2]	These options will fully vest in April 2015.

Stock_Options_Details_Textual

Stock Options (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options (Textual)
Unvested stock options	703,000
Unvested stock options, exercise price	$0.03
Stock options granted during period	703,000	100,000
Stock option granted during period, exercise price	$0.03	$0.04
Non-cash stock-based compensation expense related to employee stock options	$17,000	$179,000
Stock options vested during period	100,000	5,607,000
Stock option vested during period, exercise price	$0.04	$0.06
Estimated fair value of stock options granted	19,000	4,000
Estimated fair value of stock options vested	$4,000	$358,000
2006 Stock Option and Incentive Plan [Member]
Stock Options (Textual)
Common stock available for stock options or awards under the Stock Plan	12,500,000
Maximum percentage of shares issuable in one year to one employee	25.00%
Maximum number of shares of common stock authorized for issue under plan	12,500,000
2014 Stock Option and Incentive Plan [Member]
Stock Options (Textual)
Common stock available for stock options or awards under the Stock Plan	50,000,000
Maximum percentage of shares issuable in one year to one employee	25.00%
Maximum number of shares of common stock authorized for issue under plan	50,000,000

Equity_Purchase_and_Registrati1

Equity Purchase and Registration Rights Agreements (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 02, 2014
Equity Purchase And Registration Rights Agreements (Textual)
Purchase agreement term	3 years
Number of shares of common stock sold	4,403,403	3,618,676
Proceeds from common stock sold under equity line of credit	$162,000	$156,000
Southridge Partners II LP [Member] | Equity Purchase Agreement [Member]
Equity Purchase And Registration Rights Agreements (Textual)
Convertible agreement description			Pursuant to the terms of the EP Agreement, Southridge committed to purchase up to 40,000,000 million shares of the Company's common stock, in exchange for consideration not to exceed Ten Million ($10,000,000) Dollars. The purchase price for the shares of common stock shall be equal to 94% of the lowest daily Volume Weighted Average Price ("VWAP") of the stock during the ten trading days that comprise the defined pricing period. The Company is entitled to exercise a Put to Southridge by delivering a Put Notice, which requires Southridge to remit the dollar amount stated in the Put Notice at the end of the pricing period, provided, however, that for each day during the pricing period, if any, that the daily VWAP of the Company's common stock falls 25% or more below the Floor Price, as hereinafter defined, then the dollar amount of the Put shall be reduced by 10% for each such day.
Purchase of common stock shares			40,000,000
Southridge Partners II LP [Member] | Registration Rights Agreement [Member]
Equity Purchase And Registration Rights Agreements (Textual)
Convertible agreement description			Pursuant to the terms of the Registration Rights Agreement, in August 2014, the Company filed a registration statement with the SEC covering 40,000,000 shares of common stock underlying the EP Agreement, which was declared effective.
Dutchess Opportunity Fund II, LP [Member]
Equity Purchase And Registration Rights Agreements (Textual)
Description of put option purchase price	Equal to ninety-four percent (94%) of the lowest daily VWAP of the common stock during the five-day trading period beginning on the effective date of the Put.

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule of total deferred tax assets and valuation allowances
Current deferred tax asset - inventory reserve	$195,000	$195,000
Non-Current Deferred Tax Assets:
Net operating loss carryforwards	6,475,000	6,201,000
Stock-based compensation expense	4,242,000	1,688,000
Accrued liabilities not paid	464,000	481,000
Deferred compensation not paid within 2.5 months	432,000	115,000
Accrued interest on notes to related parties	159,000	115,000
Total long-term deferred tax assets	11,772,000	8,600,000
Total deferred tax assets	11,967,000	8,795,000
Less: valuation allowance	-11,967,000	-8,795,000
Net deferred tax assets

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule of differences in Income tax (benefit) provision
Federal tax provision at the statutory rate	34.00%	34.00%
State income tax provision (benefit), net of federal benefit	-2.20%	-2.70%
Stock-based compensation expense	-20.00%	-9.10%
Deferred compensation not paid within 2.5 months	-2.50%	-4.20%
Accrued interest not deductible for tax return purposes	-2.50%	-6.00%
Net change in net operating loss carryforwards	-2.10%	-15.50%
Increase in estimated fair value of embedded derivative liabilities	-0.30%	-3.10%
Accrued liabilities not deductible for tax return purposes	0.30%	0.40%
Officer's life insurance	0.00%	-0.20%
Total	-4.70%	-6.40%
Valuation allowance	-4.70%	-6.40%
Effective tax rate	0.00%	0.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes (Textual)
Federal tax provision (benefit) at the statutory rate	34.00%	34.00%
Increase in deferred tax assets	$3,178,000	$834,000
Unrecognized tax benefits liability
Income tax examination, Description	2010 through 2013
Penalties or interest related to income tax returns
Federal [Member]
Income Taxes (Textual)
Operating loss carryforwards	17,305,000
Operating loss carryforwards expiration date description	Expiring between 2018 and 2034.
New Jersey [Member]
Income Taxes (Textual)
Operating loss carryforwards	$7,456,000
Operating loss carryforwards expiration date description	Expiring between 2015 and 2034.

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Summary of approximate amount of base compensation and benefits
Base compensation and benefits	$10,400,971		$1,047,283
George J Coates [Member]
Summary of approximate amount of base compensation and benefits
Base compensation and benefits	16,000	[1],[2],[3],[4],[5],[6],[7]	29,000	[1],[2],[3],[4],[5],[6],[7]
Gregory G. Coates [Member]
Summary of approximate amount of base compensation and benefits
Base compensation and benefits	177,000	[8],[9]	169,000	[8],[9]
Bernadette Coates [Member]
Summary of approximate amount of base compensation and benefits
Base compensation and benefits	$4,000	[10]	$15,000	[10]
[1]	For the years ended December 31, 2014 and 2013, George J. Coates earned additional base compensation of $250,000 and $231,000, respectively, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheets at December 31, 2014 and 2013.
[2]	During the period from January 1, 2014 to July 2, 2014 and the year ended December 31, 2013, 40,191 and 68,590 shares of Series A Preferred Stock, respectively, having an estimated fair value of $100,000 and $170,000, respectively, were granted and issued to George J. Coates pursuant to an anti-dilution agreement. On July 3, 2014 181,664 shares of Series A Preferred Stock comprising all of the shares of Series A Preferred Stock previously issued to George J. Coates were converted into 181,664 shares of Series B Convertible Preferred Stock, $0.001 par value per share.
[3]	On August 1, 2014, 50,000 shares of Series A Preferred Stock with an estimated fair value of $69,000, were issued to George J. Coates as an inducement to him to consider future offers from investors to acquire substantial ownership interests in the Company as a means of raising substantial new working capital for the Company.
[4]	During the year ended December 31, 2014, George J. Coates was awarded 541,933 shares of Series B Convertible Preferred Stock with an estimated fair value of $8,070,000 for anti-dilution. Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
[5]	During the year ended December 31, 2013, George J. Coates was awarded 14,142,085 unregistered shares of the Company's common stock for anti-dilution protection related to new shares of common stock issued in 2013. The estimated value of these shares, based on the closing trading price of the stock on the dates of issuance was $430,000 which was charged to stock-based compensation expense for the the year ended December 31, 2013. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, unissued status.
[6]	In January 2013, the Company issued 20,895,046 unregistered shares of its common stock to George J. Coates in satisfaction of a deferred compensation liability consisting of 20,275,046 shares for anti-dilution protection for the year ended December 31, 2012 and a 620,000 share stock award originally granted in 2011. The value of these shares, based on the closing trading price on the dates of the anti-dilution or the date of the stock award was $1,761,000, of which $1,674,000 and $87,000 was charged to stock-based compensation expense during the years ended December 31, 2012 and 2011, respectively. On August 30, 2013, these shares were voluntarily returned to the Company for cancellation, upon which the shares were restored to the authorized, unissued status.
[7]	During the year ended December 31, 2014, George J. Coates received a compensatory award of $950,000 in the form of a non-interest bearing promissory note to compensate him for the lost benefits of ownership of the property he contributed to the Company as more fully discussed in Note 13.
[8]	Includes compensation paid in 2014 for vacation earned but not taken.
[9]	During the year ended December 31, 2014, Gregory G. Coates was awarded 40,593 shares of Series B Convertible Preferred Stock with an estimated fair value of $607,000 for anti-dilution. Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
[10]	For the years ended December 31, 2014 and 2013, Bernadette Coates earned additional base compensation of $67,000 and $57,000, respectively, payment of which is being deferred until the Company has sufficient working capital. This amount is included in deferred compensation in the accompanying balance sheets at December 31, 2014 and 2013.

Related_Party_Transactions_Det1

Related Party Transactions (Details Textual) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended			0 Months Ended	6 Months Ended	0 Months Ended
	Dec. 31, 2014	Jan. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 01, 2014	Jul. 02, 2014	Jul. 02, 2014	Jul. 03, 2014
Related Party Transactions (Textual)
Promissory notes unpaid accrued interest	$342,000
Preferred stock, par value	$0.00		$0.00
Value of anti-dilution shares of Series B Convertible Preferred Stock issued to related parties	4,511,671
Fair value of common stock issued	8,070,000
Series B Convertible Preferred Stock [Member]
Related Party Transactions (Textual)
Issuance of anti-dilution shares of Series B Convertible Preferred Stock to related parties, shares	328,838
Value of anti-dilution shares of Series B Convertible Preferred Stock issued to related parties	329
George J. Coates [Member]
Related Party Transactions (Textual)
Amount of compensation deferred	250,000		231,000
Fair value of common stock issued			430,000
Unregistered shares of common stock issued		20,895,046	14,142,085
Shares of Common Stock awarded				20,275,046	620,000
Deferred compensation liability				1,674,000
Value of anti-dilution shares of common stock issued		1,761,000		1,674,000	87,000
Promissory Note to Related Party Converted to Common Stock	950,000
George J. Coates [Member] | Series A Preferred Stock [Member]
Related Party Transactions (Textual)
Shares of Series A Preferred Stock issued			68,590			50,000	40,191
Fair value of Series A Preferred Stock issued			170,000			69,000	100,000
Shares of Series A preferred stock converted into series B convertible preferred stock									181,664
Preferred stock, par value									$0.00
George J. Coates [Member] | Series B Convertible Preferred Stock [Member]
Related Party Transactions (Textual)
Shares of Series A Preferred Stock issued								75,000
Issuance of anti-dilution shares of Series B Convertible Preferred Stock to related parties, shares	541,933
Value of anti-dilution shares of Series B Convertible Preferred Stock issued to related parties	8,070,000
Preferred Stock, Conversion Basis	Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
Gregory G. Coates [Member] | Series B Convertible Preferred Stock [Member]
Related Party Transactions (Textual)
Issuance of anti-dilution shares of Series B Convertible Preferred Stock to related parties, shares	40,593
Value of anti-dilution shares of Series B Convertible Preferred Stock issued to related parties	607,000
Preferred Stock, Conversion Basis	Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
Bernadette Coates [Member]
Related Party Transactions (Textual)
Amount of compensation deferred	67,000		57,000
Related Party [Member]
Related Party Transactions (Textual)
Effective Interest Rate	17.00%
Barry C Kaye [Member]
Related Party Transactions (Textual)
Amount of compensation deferred	170,000		40,000
Issuance of anti-dilution shares of Series B Convertible Preferred Stock to related parties, shares	2,976
Value of anti-dilution shares of Series B Convertible Preferred Stock issued to related parties	44,000
Preferred Stock, Conversion Basis	Each share of Series B Convertible Preferred Stock become convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
Deferred compensation liability	$78,000

Contractual_Obligations_and_Co2

Contractual Obligations and Commitments (Details) (USD $)	Dec. 31, 2014
Summary of Company's contractual obligations
Due Within 2015	$4,752,000
Due Within 2016	142,000
Total	4,894,000
Promissory notes to related parties [Member]
Summary of Company's contractual obligations
Due Within 2015	1,566,000
Due Within 2016
Total	1,566,000
Mortgage loan payable [Member]
Summary of Company's contractual obligations
Due Within 2015	1,448,000
Due Within 2016
Total	1,448,000
Deferred compensation [Member]
Summary of Company's contractual obligations
Due Within 2015	1,080,000
Due Within 2016
Total	1,080,000
Convertible promissory notes [Member]
Summary of Company's contractual obligations
Due Within 2015	576,000
Due Within 2016	120,000
Total	696,000
Finance lease obligation [Member]
Summary of Company's contractual obligations
Due Within 2015	72,000
Due Within 2016	22,000
Total	94,000
Settlement of litigation [Member]
Summary of Company's contractual obligations
Due Within 2015	10,000
Due Within 2016
Total	$10,000

Contractual_Obligations_and_Co3

Contractual Obligations and Commitments (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Contractual Obligations (Textual)
Compensation cost related to nonvested stock options	$7,000
Recognition period for compensation expense	4 months

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event [Member], USD $)	0 Months Ended	1 Months Ended	3 Months Ended
	Mar. 30, 2015	Feb. 28, 2015	Mar. 30, 2015
Series B Convertible Preferred Stock [Member]
Subsequent Events (Textual)
Preferred stock, par value	$0.00		$0.00
Convertible Promissory Notes [Member]
Subsequent Events (Textual)
Promissory note, principal amount issued	$409,000		$409,000
Promissory note, principal amount repaid		27,000
Accrued interest			24,000
Unregistered shares of common stock			134,424,332
Conversion of convertible promissory notes			696,000
Balance of convertible promissory notes	339,000
9.75% Convertible Promissory Note [Member]
Subsequent Events (Textual)
Promissory note, principal amount issued	52,500		52,500
Interest Rate			9.75%
Proceeds from Convertible promissory notes			50,000
Optional conversion price per share if noteholder converts	$0.06		$0.06
Promissory note conversion description			The variable conversion price is the lesser of $0.055 per share, or 70% of the average of the three lowest daily volume weighted average prices ("VWAP") over the 15 trading day period prior to the date of conversion.
Renown Power Development, Ltd [Member]
Subsequent Events (Textual)
licensing fee		100,000,000
Non-Refundable Deposit		500,000
Tentative terms of agreement, Description		Renown receives an aggregate of US$10,000,000, it is required to pay the Company 25% of all funds it receives from any and all sources until the entire US$100 million licensing fee is paid in full. In the event that Renown completes one or more capital raises aggregating US$300 million or more, the then remaining unpaid balance of the US$100 million licensing fee shall become immediately due and payable.
Outstanding licensing fee		100,000,000
Aggregate amount of capital raises		300,000,000
Ownership percentage to be placed in escrow		25.00%
Required payment of sublicensing fee		100,000,000
Sale of production parts and components		131,000
George J. Coates [Member]
Subsequent Events (Textual)
Additional deferred compensation			63,000
Balance of deferred compensation	543,000
George J. Coates [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Events (Textual)
Shares of Series B Preferred Stock issued			640,657
Fair value of Series B Preferred Stock issued			2,034,000
George J. Coates [Member] | 17% Promissory Note [Member]
Subsequent Events (Textual)
Interest Rate			17.00%
Repayment of promissory notes to related parties			58,000
Repayment of promissory notes to related parties			40,000
Gregory G. Coates [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Events (Textual)
Shares of Series B Preferred Stock issued			43,614
Fair value of Series B Preferred Stock issued			138,000
Barry C Kaye [Member]
Subsequent Events (Textual)
Additional deferred compensation			13,000
Balance of deferred compensation	92,000
Barry C Kaye [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Events (Textual)
Shares of Series B Preferred Stock issued			3,414
Fair value of Series B Preferred Stock issued			11,000
Bernadette Coates [Member]
Subsequent Events (Textual)
Additional deferred compensation	17,000
Balance of deferred compensation	141,000
Bernadette Coates [Member] | 17% Promissory Note [Member]
Subsequent Events (Textual)
Interest Rate			17.00%
Repayment of promissory notes to related parties			$9,000